Aus SOUTHPOINTE wird XCEED BIOTECHNOLOGY (WKN 906545) - 500 Beiträge pro Seite

[ixilon]

19 March 2004

The Company Announcement Platform Australian Stock Exchange Limited Level 5 Bridge Street SYDNEY NSW 2000


Dear Sir/Madam

INVESTMENT IN POLYMERCO PTY LTD AND ACQUISITION OF BORON MOLECULAR LTD

The Directors of Southpointe Limited (Southpointe or the Company) are pleased to advise that the Company has reached agreement:

• with the Commonwealth Scientific and Industrial Research Organisation (“CSIRO”) whereby, for 50% of the equity in PolymerCo Pty Ltd (“Polymerco”), a new company formed by Southpointe, CSIRO will grant to Polymerco exclusive, world wide, royalty free rights to a new biodegradable, biocompatible polymer developed by CSIRO’s Division of Molecular Science, with potential applications in orthopaedics, dental, drug delivery, cartilage and wound repair (the “Platform Technology”); and

• to acquire 100% of Boron Molecular Ltd (“Boron Molecular”), a chemistry company providing organoboron compounds and services to the pharmaceutical and biotechnology industry under an exclusive worldwide licence,

having entered into binding Term Sheets for the investment in Polymerco and the acquisition of Boron Molecular. The Board has resolved to proceed with both transactions, subject to due diligence and shareholder approval.

Southpointe Ltd Proposed New Investment Focus

The directors of the Company are of the opinion that the Life Sciences sector in Australia will continue to grow over the coming decades. The expected growth and investor interest in this sector has been driven by recent significant positive research and clinical outcomes by existing Australian biotechnology companies. Such outcomes have and will continue to attract the attention of international investors and pharmaceutical and biotechnology companies.

The Company will change its name to Xceed Biotechnology Limited (“Xceed”) and the Company will become an international biotechnology investment company, focusing on investment in revenue producing and research based leading edge technologies.

Xceed will initially focus on;

• the development and commercialisation of Polymerco’s Platform Technology; and

• increasing the sales of Boron Molecular’s range of organoboron products and related services.

Quelle: http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=257898

WKN 906545
Symbol SOU
http://www.xceedbiotech.com

[ixilon]

[ixilon]

Xceed and CSIRO to co-invest in polymer technology
By RWE Australian Business News, 23 Apr 2004

Sydney - Friday - April 23: (RWE) - Southpointe Ltd, to be
renamed Xceed Biotechnology Ltd, has entered a co-investment arrangement
with the Commonwealth Scientific and Industrial Research Organisation to
fund a biotechnology company focused on a polymer platform technology.
Southpointe has also purchased a chemistry company, Boron
Molecular Ltd, whose technology also originates from the CSIRO.

A prospectus to raise $4.5 million has been lodged with the ASIC
and the company plans to re-list on the ASX as Xceed on May 14.

It is pursuing a strategy to become a life science investment
company, focusing on investment in revenue-producing and research-based
leading edge technologies.

In addition to the $7 million in cash held by Southpointe, the
company will raise $4 million by offering 20 million shares to the
public at 20c a share.

The offer is fully underwritten by Euroz Securities.

On re-listing Xceed will have a market capitalisation of about
$17 million based on the 20c issue price.

Xceed will have two core assets in its portfolio - Polymerco Pty
Ltd and Boron Molecular Ltd.

Core technologies of each company have been developed by the
CSIRO.

Xceed will hold a 50 per cent stake in PolymerCo, which will
have exclusive worldwide, royalty-free rights to a new biodegradable,
biocompatible polymer developed by the CSIRO`s Division of Molecular
Science.

This platform technology has potential applications in
orthopaedics, dental, drug delivery, cartilage repair and wound repair.

In addition to its investment in Polymerco, Xceed will acquire
100 per cent of Boron Molecular Ltd, a chemistry company providing
organoboron compounds and services to the pharmaceutical and
biotechnology industry under an exclusive worldwide licence from CSIRO.

The offer is expected to close on May 5.

Shares in Southpointed today rose 0.5c to 4.8c.

Quelle:http://www.investorweb.com.au/marketmonitor/mb_story_details…

[ixilon]

Southpointe acquires interest

The Company has identified two investment opportunities in the Life Science sector and conditional contracts, subject to shareholder approval, have been entered into with respect to these investments which, if approved, will transform the Company into an international Life Science investment company, to be renamed Xceed Biotechnology Limited (Xceed). Xceed will focus on investment in revenue producing and research based leading edge patentable technologies.

The Company proposes to make two initial investments in the Life Science sector being:

- a $5.1 million investment into Polymerco with the retention of 50% equity ownership;
and
- the acquisition of 100% of the issued capital of Boron Molecular.

Broadly, the Company will initially focus on:

- the development and commercialisation of Polymerco’s novel biodegradable polymers; and
- increasing the sales of Boron Molecular’s range of products and collaborative partners.



Quelle:http://www.xceedbiotech.com/index.phtml

[ixilon]

Dear Shareholder,

On behalf of Southpointe Limited (Southpointe or Company), I am pleased to invite you to participate in the
future growth and success of the Company as we transform Southpointe into a biotechnology investment company
to be named Xceed Biotechnology Limited (Xceed).

Over the past two years your Board has been investigating opportunities in a number of sectors and we are
encouraged by the substantial international interest and success that Australian Life Science companies and
Australian technologies have enjoyed during that period.

As such when presented with an opportunity to invest in the biotechnology sector through the 50% ownership of
a polymer research and development company, Polymerco Pty Limited (Polymerco), and 100% acquisition of Boron
Molecular Limited (Boron Molecular), an existing revenue generating chemistry company, the Board saw this as
an excellent opportunity.

Drawing on their knowledge in the design of new polymers and their expertise in the area of polyurethane science,
Australia’s Commonwealth Scientifi c and Industrial Research Organisation (CSIRO) Molecular Science Division has
invented and sought patent protection for a new platform technology which we believe has the potential to become
the next generation polymers in the area of commercial biodegradable polymers.

Under a worldwide royalty free exclusive licence from CSIRO, Polymerco will further develop the novel biodegradable
polymers, which provides the fl exibility to alter structure and properties for a range of potential biomedical uses in
orthopaedics, orthodontics, drug delivery, wound care, tissue engineering and cartilage repair.

Importantly, the biomaterial can be formulated as an injectable gel which sets to a porous cross-linked network with
potentially unmatched mechanical and bioadhesive properties.

Since 2001, Boron Molecular has been utilising exclusively licensed technology from CSIRO Molecular Science
Division to provide high-value organoboron compounds and chemistry services to the global pharmaceutical and
biotechnology industry. Having established a large customer base domestically and overseas, Boron Molecular is
seeking an injection of capital to enable the business to realise growth opportunities and further commercialise,
market and develop their organoboron technology and chemistry related services.

Southpointe is very pleased to have obtained access to two leading-edge CSIRO Molecular Science Division developed
technologies. As one of the world’s largest and most diverse scientifi c global research organisations the Company
believes CSIRO’s work and technologies affect all Australians. Southpointe understands that CSIRO’s 6,500 local and
international staff are focused on providing new ways to improve Australian’s quality of life, as well as the economic
and social performance of a number of industry sectors through research and development.

With the support of experienced international biotechnology executives and access to CSIRO developed technologies,
I look forward to seeing Southpointe develop into another Australian international biotechnology success.

I therefore invite you to participate in the potential success of Southpointe as we strive to transform it into a well
recognised biotechnology investment company.

Yours sincerely

Karl Paganin
CHAIRMAN
22 April 2004

Quelle:http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=259928

[ixilon]

28 April 2004

Appendix 3B-Issue of shares & unlisted options

http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=260224

[ixilon]

Heute vom Handel ausgesetzt

29 April 2004

Southpointe Limited

SUSPENSION FROM OFFICIAL QUOTATION

The securities of Southpointe Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the outcome of resolutions to be considered by shareholders at a general meeting to be held on Friday 30 April 2004.

If shareholders approve the proposed change of activities, the securities of the Company will remain suspended until the Company has complied with Chapters 1 and 2 of the listing rules.

Brendan O`Hara
Manager Companies

Quelle: http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=260444

[nonnenkloster]

Ixilon,

du kennst Dich ja bestens aus. Kannst Du mir sagen, welchen Inhalt genau die “Chapters 1 and 2 of the listing rules” der Börse besagen und wann Du meinst, dass das Unternehmen diese erfüllen wird und somit die Aktie wieder gehandelt wird? Gleich nach Beendigung der HV und der Zustimmung der Aktionäre oder erst zu einem spätern Termin?

[ixilon]

30 April 2004 11:45 ASX Perth

Southpointe Limited – Reorganisation

Participating Organisations are advised that the reorganisation of capital of Southpointe
Limited (the “Company”) will become effective on Monday 3 May 2004.

The reorganisation is by way of consolidating every seven fully paid ordinary shares in the capital of the Company into one fully paid ordinary share.

The Company is currently suspended


The following timetable will apply.

30 April 2004
Shareholder approval

3 May 2004
Trading would normally commence in the reorganised securities on a deferred settlement basis.
ASX Code : SOUDA

7 May 2004
Last day for the Company to register transfers on a pre-reorganisation basis.

10 May 2004
First day for the Company to register securities on a post reorganisation basis.

14 May 2004
Despatch day. Deferred settlement trading would normally end ASX Code : SOU


The securities of the Company remain suspended pending compliance with listing rule 11.1 and chapters 1 and 2 of the listing rules.


ASX Contact: Jill Hewitt
Business Unit Companies Perth
Ext.No: 30 April 2004

[ixilon]

Hab das mal durch den Babel Fisch Übersetzer geschickt



April 30 2004 11:45 ASX Perth


Southpointe Limited – Reorganisierung

Teilnehmende Organisationen werden geraten, daß die Reorganisierung des Kapitals von Southpointe Limited (die "Firma") am Montag Mai 3 2004 wirkungsvoll wird.

Die Reorganisierung ist über das Vereinigen jeder sieben völlig gezahlten Stammaktien am Kapital der Firma in eine, die völlig Stammaktie gezahlt wird.

Die Firma wird z.Z. verschoben


Der folgende Zeitplan trifft zu.

April 30 2004
Aktionärzustimmung handelnder

Mai 3 2004
Würde normalerweise in den reorganisierten Aktien auf einer aufgeschobenen Regelung Grundlage beginnen. ASX Code: SOUDA

Mai 7 2004
Letzter Tag, damit die Firma Übertragungen auf eine Vorreorganisierung Grundlage registriert.

Mai 10 2004
Erster Tag, damit die Firma Sicherheiten auf einer post-reorganisierunggrundlage registriert.

Mai 14 2004
Abfertigung Tag. Das aufgeschobene Regelung Handeln würde normalerweise ASX Code beenden: SOU


Die Aktien der Firma bleiben während Befolgung Auflistung Richtlinie 11.1 und Kapitel 1 und 2 der Auflistung Richtlinien verschoben.

ASX Kontakt: Jill Hewitt
Unternehmenseinheit-Firmen Perth
Ext.No: April 30 2004

Quelle: http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=260586

[ixilon]

11.00 AM, Friday 30 April 2004

Results of General Meeting

Approved

http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=260590

[nonnenkloster]

Tja, alle Tagesordnungspunkte der HV wurden angenommen. Heißt das unter

http://www.asx.com.au/asxpdf/20040430/pdf/3lfnx6kl7w2s6.pdf

dass jetzt 7 Southpoint Aktien zu einer neuen werden? Und zu welchem Kurs? Bedeutet das, dass die Aktien ab Montag nur noch 1/7 Wert sind?

[ixilon]

Reverse Split

Zusammenfassung mehrerer Aktien zu einer. Gegenteil eines Aktiensplit. In den USA übliche Maßnahme, wenn ein optisch höherer Kurswert erreicht werden soll. Zum Beispiel werden bei einem Reverse Split im Verhältnis 1:5 je fünf alte Aktien zu einer neuen zusammengefasst. Ein Reverse Split wird zum Beispiel angewendet, um ein Delisting an der Nasdaq zu verhindern, das dort droht, wenn der Aktienkurs unter einen Dollar fällt.

Quelle: http://www.google.de/search?q=cache:xaDDF3izriEJ:home.t-onli…

Das heißt für 7 alte Aktien gibt es 1 neue.

Kurs in Frankfurt 0,028 € nach dem Reverse Split 0,196 €

[ixilon]

Background on Boron Molecular

Boron Molecular is a chemistry company providing compounds and chemistry services to the pharmaceutical and biotechnology industry. It began trading in April 2001. Its business is based upon an exclusive, worldwide right to commercially exploit unique organoboron technology licensed from CSIRO.

Boron Molecular participates in the international drug discovery market by providing ‘building block’ compounds and chemistry services to clients at every stage of the drug development pipeline. The advantage of this revenue model is that Boron Molecular generates income streams irrespective of the ultimate success of drugs being developed by its clients.

Boron Molecular’s three competitive advantages are:

- its compounds and processes (protected by patents and patent applications);

- price competitiveness in the global market; and

- the specialist chemistry skills of its scientists.

Boron Molecular is becoming recognised internationally for these three attributes and from inception has been adding new compounds to its catalogue (now in excess of 300 compounds), securing additional distribution channels, implementing effective marketing campaigns to increase clients and potential clients and is looking to establish an overseas presence in the world’s largest market, the USA. In addition, Boron Molecular is working to build critical mass, which will benefit its positioning as a provider of specialist chemistry services.

In the three years since incorporation, Boron Molecular has made significant commercial progress, including:

- establishing income streams from both its compound and chemistry services businesses;

- recruiting appropriately skilled chemistry specialists;

- expanding its intellectual property base; and

- installing an advanced laboratory in Noble Park, Melbourne.

These endeavours have built a customer base and platform from which Boron Molecular now wishes to expand internationally.

HP von Boron Molecular
http://www.boronmolecular.com/

[ixilon]

Southpointe Ltd.

In Übereinstimmung mit der Heimatbörse wird die Preisfeststellung der Aktien der
Gesellschaft

von heute bis einschließlich 14. Mai 2004
ausgesetzt.

Wertpapier-Kenn-Nummer : 906 545
ISIN : AU000000SOU4
Markt : Freiverkehr - variabel
Skontroführer : 1170 Berliner Freiverkehr (Aktien) AG

Berlin, den 30. April 2004
GESCHÄFTSFÜHRUNG DER BÖRSE BERLIN-BREMEN

[ixilon]

Background on Polymerco

Polymerco was incorporated on 27 February 2004 for the purpose of becoming a Life Science company focused on developing products to improve medical and surgical outcomes, based on a portfolio of licensed biomaterials which are currently seeking patent protection.

CSIRO will provide Polymerco with a worldwide royalty free exclusive licence to the relevant existing intellectual property, any new related patents and improvements, in consideration for which CSIRO will receive 50% of the equity in Polymerco.

The technology that will underpin the sustainability of Polymerco is based on innovative chemistry developed within the CSIRO’s Division of Molecular Science. That technology represents the latest breakthrough in the field of biomaterials for leading CSIRO polymer scientists who have established a track record as polymer innovators. The technology being licensed to Polymerco builds on a previous CSIRO commercially successful polymer innovation and a new generation of biostable polyurethanes for biomedical applications now marketed commercially as Elasteon™.

In the emerging field of tissue engineering there is a significant need for new types of biodegradable polymers with improved properties. The new technology was developed to potentially meet a number of demanding requirements, ranging from the ability of the polymers to provide mechanical support during tissue growth and gradually degrade to biocompatible products, to more demanding requirements such as the ability to incorporate cells, growth factors and provide cell-conductive and inductive environments. Many of the currently available degradable polymers do not meet all of these requirements. Furthermore, the development of injectable polymers is becoming increasingly attractive in tissue engineering applications requiring minimally invasive procedures.

As a class of synthetic polymers, polyurethanes offer numerous opportunities to tailor materials with properties and chemical composition to suit soft tissue as well as hard tissue engineering applications.


Polymerco Platform Technology
The requirements for polymer performance within the biological environment have been a critical factor in limiting the possible compositions to a relatively small number that, to date, have proven useful in medical devices.

Utilising its knowledge in the design of new polymers that are ‘fit for function’ and expertise in the area of polyurethane science, CSIRO has invented and sought patent protection for a new series of injectable biodegradable polyurethane-based polymers (the Platform Technology ), which the Company believes have the potential to become the next generation polymers in the area of commercial biodegradable polymers with application in orthopaedics, orthodontics, cartilage repair, tissue engineering, drug delivery and wound care.

The Platform Technology was developed primarily for use as an injectable polymer in biomedical applications. These degradable polymers were developed as a two-part system which react after mixing to form a cross-linked three dimensional polymer network in-situ.

The polymer structure may be tailored to generate a material with the desired mechanical properties, porosity, adhesiveness, and degradation profile, through selection of the appropriate mixture of pre-polymers. The system was also designed to potentially facilitate delivery of cells, bioactive agents or pharmaceuticals.

Quelle: http://www.xceedbiotech.com/investment/polymerco_pty_ltd/ove…

[ixilon]

05 May 2004

The Manager
Company Announcements
Australian Stock Exchange Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

CLOSING OF PROSPECTUS

We refer to the Company’s prospectus lodged at the Australian Securities and Investments Commission on 22 April 2004.
The Board of Directors of Xceed Biotechnology Limited is pleased to advise that the offer has been oversubscribed and closed as at the 5th May 2004.

Yours sincerely

KARL PAGANIN
Chairman 040505

Quelle:http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=261058

[ixilon]

Appendix 4C - Monthly Report for April 2004

http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=261218

[ixilon]

13th May 2004

The Manager
Company Announcements
Australian Stock Exchange Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement


RE-LISTING OF XCEED BIOTECHNOLOGY LIMITED
The company is pleased to advise that its shares will begin trading again on Wednesday 19th
May 2004 under the new ASX code XBL.

David McAuliffe
Chief Executive Officer

Quelle: http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=261523

[ixilon]

14 May 2004

Notice of Investment Roadshow

By e-lodgement

Xceed Biotechnology Limited (Xceed) plans to initiate an interstate roadshow to stockbroking and financial institutions.

Company briefings have been confirmed in:

• Sydney (17-19 May)
• Perth (20-21 May)
• Melbourne (23-25 May)

The purpose of the national roadshow is to expand the Company’s retail and institutional shareholder base and to generate additional investor interest in the Company.

The Company presentation confirms that the funds recently raised will used to expand sales in Boron Molecular Ltd and accelerate the development and commercialisation of a revolutionary new polymer technology that has been developed by scientists at CSIRO Molecular Science, and exclusively licensed to a new company formed by Xceed called Polymerco Pty Ltd.

Any parties interested in hearing more about the Company’s plans should contact the company.

David McAuliffe
Chief Executive Officer

[e-mail]
0408 994 313
www.xceedbiotech.com

Quelle: http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=261604

[ixilon]

17th May 2004

CSIRO and Polymerco Inventors to present at the 7th World BioMaterials Congress

Xceed Biotechnology Ltd are pleased to announce that the CSIRO Molecular Science inventors of Polymerco Pty Ltd technology, a revolutionary new biodegradable polymer for medical device applications, will be presenting at the 7th World BioMaterials Congress to be held in Sydney from the 17 – 21 May at the Sydney Convention & Exhibition Centre, Darling Harbour Sydney, Australia.

The presentations and papers are scheduled for:

• Effect of Cross Linking on Creep Resistance of Biostable Polyurethanes – Thursday 20 May (Bayside Room)

• Effect of Sulfonium Zwitterions on Properties and Degradation of Biodegradable Polyurethanes – Thursday 20 May (Tumbalong Ballroom 1700 - 1715)

• Injectable Biodegradable Polyurethanes for Cartilage Repair: Evaluation of Biocompatibility and Biodegradability (Exhibition Level 1 0800 - 1800)

• Biodegradable Polyurethane for Fused Deposition Modelling - Friday 21 May (Harbourside Auditorium 0915 - 0930)

• Injectable Biodegradable Polyurethanes for Tissue Engineering – Friday 21 may (Harbourside Auditorium 2 1600 - 1630)

More information
Dr Thilak Gunatillake, CSIRO Molecular Science: 03 9545 2501, 0409 253 325
Mr David McAuliffe, Xceed Biotechnology Ltd: 08 9278 1866, 0408 994 313

Quelle: http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=261652

[ixilon]

17th May 2004

CSIRO and Polymerco Inventors to present at the 7th World BioMaterials Congress

Xceed Biotechnology Ltd are pleased to announce that the CSIRO Molecular Science inventors of Polymerco Pty Ltd technology, a revolutionary new biodegradable polymer for medical device applications, will be presenting at the 7th World BioMaterials Congress to be held in Sydney from the 17 – 21 May at the Sydney Convention & Exhibition Centre, Darling Harbour Sydney, Australia.

The presentations and papers are scheduled for:

• Effect of Cross Linking on Creep Resistance of Biostable Polyurethanes – Thursday 20 May (Bayside Room)

• Effect of Sulfonium Zwitterions on Properties and Degradation of Biodegradable Polyurethanes – Thursday 20 May (Tumbalong Ballroom 1700 - 1715)

• Injectable Biodegradable Polyurethanes for Cartilage Repair: Evaluation of Biocompatibility and Biodegradability (Exhibition Level 1 0800 - 1800)

• Biodegradable Polyurethane for Fused Deposition Modelling - Friday 21 May (Harbourside Auditorium 0915 - 0930)

• Injectable Biodegradable Polyurethanes for Tissue Engineering – Friday 21 may (Harbourside Auditorium 2 1600 - 1630)

More information
Dr Thilak Gunatillake, CSIRO Molecular Science: 03 9545 2501, 0409 253 325
Mr David McAuliffe, Xceed Biotechnology Ltd: 08 9278 1866, 0408 994 313

Qulle: http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=261652

[ixilon]

17 May 2004

Reinstatement to Official Quotation(XCEED Biotechnology Ltd)

ASX Code : XBL

http://stocknessmonster.com/news-item?S=SOU&E=ASX&N=261654

[ixilon]

Media Release

Wednesday, 19 May 2004

Xceed Biotechnology Ltd lists on ASX at a premium

Biotechnology investment company Xceed Biotechnology Ltd (Xceed) made its debut
on the ASX today (ASX: XBL) with its shares listing at $0.30 cents - a 50% premium
to its issue price of $0.20.
Xceed, (formally Southpointe Limited), completed a capital raising of $4.5 million by offering
22.5 million shares at $0.20 cents per share, which closed oversubscribed. The $4.5 million
raised is additional to the $7 million in cash held by Xceed. The offer was fully underwritten by
Euroz Securities Ltd.

Xceed Chief Executive Officer, Mr David McAuliffe said Xceed’s agreement with CSIRO
Australia, for Xceed to form and fund a new biotechnology company PolymerCo Pty Ltd,
focused on a biodegradable polymer* platform technology, had been very well received
by investors. In addition the 100% acquisition of Boron Molecular Ltd provided the
company with revenues.

“Xceed now has two core assets in its portfolio, 50% of PolymerCo Pty Ltd and 100% of
Boron Molecular Ltd with the core technologies of each company having been developed
by CSIRO,” he said.

“Xceed will form and invest $5.1 million into PolymerCo and CSIRO will provide access
to the technology, after which each of CSIRO and Xceed will own 50 percent of the
company. The revolutionary new biodegradable polymer technology has been developed
by scientists at CSIRO Molecular Science Division and exclusively licensed to
PolymerCo Pty Ltd.”

* A polymer is a substance made of many repeating chemical units or molecules. The term polymer is often used in place of plastic or rubber.

Dr Annabelle Duncan, Chief of CSIRO Molecular Science said the polymers based on
the technology can be biodegradable and biocompatible, can be formulated as an
injectable gel which cures in-situ or on-demand, promotes tissue growth and has a
controllable degradation rate.

“There has been a rapid growth in the area of tissue engineering which has led to a
requirement for new types of polymers. The porous polymer structure of PolymerCo’s
new polymer permits regrowth of the body’s own tissues to restore normal function.”

“Synthetic polymers offer a number of advantages over ceramic and natural polymer
based materials and it is envisaged that PolymerCo’s polymer could be tailored for
applications in orthopaedics, orthodontics, drug delivery, wound care, tissue engineering
and cartilage repair,” Dr Duncan said.

Mr McAuliffe said the formation of PolymerCo Pty Ltd was an exciting development and
an example of CSIRO’s commercialisation strategy in action.

“We are looking forward to a profitable relationship with CSIRO as we progress the
technology through to products.”
He said Boron Molecular, a chemistry company providing organoboron compounds and
services to the pharmaceutical and biotechnology industry under an exclusive world-wide
licence from CSIRO, and which Xceed now fully owns, would continue to increase the
sales of its products and services internationally.

“Xceed’s Board of Directors has a wealth of expertise in biotechnology, commercialisation
and research and development both in Australia and overseas. The Board believes the Life
Science sector in Australia will continue to grow over the coming decades and we are well
positioned to capitalise on this growth potential,” Mr McAuliffe said.

“As an international biotechnology investment company, Xceed will also continue to
search for new growth opportunities to generate shareholder wealth,” he said.

ENDS

For further information contact Margie Livingston, Porter Novelli on 0438 661131.

Quelle: http://www.xceedbiotech.com/images/3-XceedASX_No2_19May04.pd…

[ixilon]

MEDIA RELEASE

APPOINTMENT OF POLYMERCO PTY LTD NON-EXECUTIVE DIRECTOR

The Company is pleased to announce effective the 20 May 2004, the appointment of Mr Bruce Rathie as a Non-Executive Director of its subsidiary, Polymerco Pty Ltd.

Mr Bruce Rathie is currently the National Executive Director of the Australian Institute of Management and holds degrees in law, commerce and business. Bruce is also a Fellow of AICD and AIM and is a member of Chartered Secretaries Australia and the Securities Institute. He is a former partner in a major Australian legal firm and was Senior In House Counsel to Robert Holmes a Court’s Bell Resources in the mid ‘80’s. He studied his MBA in Geneva and then went into investment banking which took him to New York for 3 years returning to Sydney in 1990. He spent the ‘90’s in the finance industry in Sydney, the last 5 years as a Director of Investment Banking and Head of the Industrials Group at Salomon Smith Barney where he handled the firm’s role in the privatizations of Qantas, Commonwealth Bank and Telstra. He has been in business and consulting since 2000 and has held positions on the boards and has advised boards of private and ASX listed companies during this period.

Commenting on the appointment, Chief Executive Officer of Xceed Biotechnology Ltd, Mr David McAuliffe said “ We are extremely pleased to welcome Mr Rathie onto the Board of Polymerco Pty Ltd. His extensive international legal and capital market experience will assist the company enormously as we seek to progress the development of the polymer over the coming two years”.

Quelle: http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=261906

[ixilon]

Rückgang nach Reverse-Split fast wieder aufgeholt.

[nonnenkloster]

Also, ich verstehe das nicht,

da werden zum Teil täglich nur ganz geringe Stückzahlen gehandelt -bspw heute:

Kurs: 0,195, Anzahl 45 Stück, das macht 8,19 Euro. Eine Transaktion kostet via Bank oder online doch sicher ca. 10 – 12 Euro, also mehr als der Einsatz. Wer kauft/verkauft solche großen Volumen bei dieser Aktie? Und das ist kein Einzelfall…Das habe ich noch nicht erlebt

[ixilon]

@ nonnenkloster,

das kann ich Dir auch nicht erklären,
habe es aber auch schon häufig gesehen.


Heute bei Morphosys:

von wachholder 27.05.04 14:42:32 Beitrag Nr.: 13.241.267 13241267
Dieses Posting: versenden | melden | drucken | Antwort schreiben MORPHOSYS AG

wer verkauft denn 2 Stück?
Da sind die Transaktionskosten ja höher als der ganze Umsatz.



Xceed Biotechnology Ltd. A0CBF5
FSE
Akt. Kurs 0,20
27.05.04 16:15
Tagesvolumen 613 (auch nicht gerade hoch)

Aber wie Du in #26 siehst steigt das Volumen bei Xceed in Australien, nur noch eine Frage der Zeit, bis er bei uns auch steigt.

Gruß
ixilon

[liebes]

Indem bspw. jemand als Käufer nur eine Teilausführung ergattert, während ein Verkäufer eine Verfielfachung realisiert...

Der Wert ist bislang in wenigen Infosystemen korrigiert, Market Maker und Finanztreff sind noch nicht auf dem Laufenden, mein Online-Broker läßt auch noch keine gescheiten Verkaufsoptionen zu (beschränkte Platzwahl). Hoffe, daß sich das bald ändert, weil so wie es ist, kein richtiger Handel stattfinden kann !

Tschüß.

[liebes]

Außerdem werden so bei marktengen Werten die Bids und Asks ausgelotet, aber wie gesagt, bei den aktuellen Verhältnissen nicht glaubwürdig. AU gibt aber einen guten Marktüberblick und da sieht der Wert sehr heiß aus...

[ixilon]

DANKE liebes, für die Erklärung

Glaube auch das Wert heiß ist.

Gruß
ixilon

[ixilon]

Da fehlte natürlich ein "der".

[ixilon]

[ixilon]

24.05.2004

Breakthrough polymer for bone repair

A breakthrough in polymer development means that soon there may be a radical new treatment for people with broken bones - a special kind of material that can ’glue’ the bone back together and support it while it heals.

The material is designed to break down as the bone regrows leaving only natural tissue.

Scientists at CSIRO Molecular Science have developed a biodegradable polymer that can be used in the human body. Not only is it biodegradable and biocompatible, it can be formulated as an injectable gel which cures in-situ or on-demand by promoting tissue growth. The polymer’s rate of degradation can also be controlled.

"Synthetic polymers offer a number of advantages over ceramic and natural polymer-based materials," says CSIRO Molecular Science Chief, Dr Annabelle Duncan,

"We envisage that this polymer technology could be tailored for applications in orthopaedics, orthodontics, drug delivery, wound care, tissue engineering and cartilage repair," Dr Duncan says

One of the inventors of the polymer, Dr Thilak Gunatillake, plans to apply it initially in the form of a bone glue for fracture repair.

He says that the material has a distinct advantage in this area due to its combination of injectability, adhesiveness and excellent mechanical strength.

Further research is planned to demonstrate the polymer’s ability to deliver cells or biological agents to accelerate tissue regrowth.

"The use of the polymer for guided bone regrowth is not only applicable to the orthopaedic area, but also in related applications such as periodontal surgery and dental implants", Dr Gunatillake says.

A spin-off company, Polymerco Pty Ltd, has been established by CSIRO and Xceed Biotechnology to develop this revolutionary new biodegradable polymer technology for medical device applications.

"Xceed will invest $5.1 million into Polymerco and both CSIRO and Xceed will own 50 per cent," says the Chief Executive Officer of Xceed Biotechnology, Mr David McAuliffe,

"The formation of PolymerCo Pty Ltd is an exciting development and an example of CSIRO’s commercialisation strategy in action. We are looking forward to a profitable relationship with CSIRO as we progress the technology through to products."

CSIRO and Polymerco inventors are presenting papers on the new technology at the 7thWorld Biomaterials Congress in Sydney from 17 to 21 May, 2004.

More information:

Dr Thilak Gunatillake, CSIRO Molecular Science, 03 9545 2501, mobile: [phone]
Mr David McAuliffe, Xceed Biotechnology, 08 92781866

Media Assistance:

David Down, CSIRO Molecular Science, 02 9490 5220, mobile: [phone]
Email: [e-mail]

Margie Livingston, Porter Novelli, mobile: [phone]
Email: [e-mail]

Quelle: http://www.innovations-report.com/html/reports/materials_sci…

[ixilon]

[csac1129]

Ich habe gestern zufällig eine Seite gefunden, die sich mit Nanoaktien und Biotech auseinander setzt. www.nanoinvest.de
Ich habe nach die Empfehlungen von nanoinvest.de 2 Aktien gekauft(ich wurde darauf aufmerksam) und bin schon 14% bzw. 11% im Gewinn. Schaut euch mal. Es sieht super aus. Ich habe ein mail an die 2 Herren geschickt mit ein PAar fragen und ich habe ein rasches Antwort bekommen. Auch das Börsenbrief habe ich heute bekommen. 8 Seite mit Analyse von dem Sektor. Ich bin überzeugt. Ich würde mich mal interesieren ob jemand von euch jungs schon mit denen Erfahrung gemach hat?
Danke
lg Helmut

[ixilon]

8 June 2004

The Manager
Company Announcements
Australian Stock Exchange Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

Dear Sir,

We enclose a copy of a Media Release titled “Proposed Appointment of Xceed Biotechnology Ltd Non-Executive Chiarman.”

Yours sincerely

DAVID McAULIFFE
Chief Executive Officer

________________________________________________________

8 June 2004

MEDIA RELEASE

PROPOSED APPOINTMENT OF XCEED BIOTECHNOLOGY LIMITED CHAIRMAN

Xceed Biotechnology Limited (“Xceed” or “the Company”), today announced that Dr Michael Dalling, formerly Group General Manager – R&D of ASX-listed Nufarm Limited, will become Chairman of the Company, effective 1 July 2004.

Mr Dalling will replace current Chairman, Mr Karl Paganin, who has been heavily involved in restructuring the Company and in securing its portfolio of biotechnology assets.

Prior to joining Nufarm in 1999, Dr Dalling was Managing Director of the Strategic Industry Research Foundation Limited, a joint initiative of the Victorian Government and CSIRO, and Managing Director of Calgene Pacific Pty Ltd, one of Australia’s first biotechnology companies.

Dr Dalling holds a master’s degree in agricultural science from the University of Melbourne and a PhD from the University of Illinois.

“Michael will bring to the Company extensive experience of technology development and commercialization” Mr Paganin said. “His proven leadership and international experience will be a tremendous asset for the Company”.

Xceed Biotechnology Limited is a new ASX-listed Life Science investment and management company. Xceed’s first two investments are:

• 50% interest in newly established Polymerco Pty Ltd which is initially focused on developing orthopaedic and orthodontic products based on proprietary biomaterials developed by CSIRO; and

• 100% ownership of Boron Molecular Limited, which provides proprietary “building block” compounds and services to the biotechnology and pharmaceutical industries.


The Company would like to record its thanks and gratitude to Mr Paganin for the significant contribution he has made towards the Company’s development.

For further information:
David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited

Tel: [phone] abn: 79 009 181 006

Quelle: http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=262863

[nonnenkloster]

Warum hat eigentlich diese Aktie seit einiger Zeit eine Liquidität gleich Null? Nichts tut sich hier, nur in Australien wird eifrig gehandelt…

[ixilon]

NEWS

10 June 2004

The Manager
Company Announcements
Australian Stock Exchange Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000

By e-lodgement

Dear Sir

We enclose a copy of a Media Release titled “Polymerco Forms an Alliance with AorTech Biomaterials.”

Yours sincerely

DAVID McAULIFFE

Chief Executive Office

__________________________________________________________


10 June 2004

MEDIA RELEASE

POLYMERCO FORMS AN ALLIANCE WITH AORTECH BIOMATERIALS

Xceed Biotechnology Ltd (“Xceed”) is pleased to announce Polymerco Pty Ltd (“Polymerco”) and AorTech Biomaterials (“Aortech”) have entered into an agreement under which Polymerco’s novel biodegradable polyurethane technology will be scaled-up, stabilised and manufactured at AorTech’s ISO certified Melbourne Australia Technology Centre. Polymerco is an operating subsidiary of Xceed that has acquired a license to a revolutionary biodegradable polyurethane technology from CSIRO. It is envisaged that this material will find applications in orthopaedics, wound repair, drug delivery and stents. Dr Ian Griffiths, (CEO Polymerco), said ‘We are delighted to reach a general agreement with AorTech and after some applied development work Polymerco will be ready to engage the considerable talents of the AorTech group.’ AorTech Biomaterials is a Melbourne based manufacturer of the biostable polyurethane technology Elast-Eon, which is currently being supplied into numerous medical device development programmes. AorTech has licences with major medical device company’s in the fields of cardiovascular surgery and interventional cardiology. Access to the skills, equipment and personnel already established by AorTech for the manufacture of materials used in critical long term implants will ensure the rapid scale-up and supply of the new polymer technology.

Quelle: http://www.xceedbiotech.com/images/xceed-8-1-siibo.pdf

Gruß
ixilon

[Maniatis]

Habe auch noch ein paar Southpointe`s im Depot. Damals für 0,008 gekauft! Top-Kauf! Gaaanz unten eingestiegen, allerdings nur für 50 EUR, weil die Order nicht komplett ausgeführt wurde.

Sin doch gesplittet worden. 3:1, oder?

Ich habe jetzt nur noch 456,8756 St. im Depot! Sogar die Kommazahl wird bei der DIBA angezeigt. Die bleiben dann für immer im Depot oder wie?

LG

[ixilon]

@ Maniatis

Sieben alte Aktien wurden in eine neue Aktie getauscht.

Ich glaub wir werden mit dieser Aktie noch viel Spaß haben,
neue Ausrichtung der Firma,
jetzt noch völlig unbekannt,
hat sich jetzt auf dem 7th World BioMaterials Congress präsentiert,
und eine erste Roadshow in
• Sydney (17-19 May)
• Perth (20-21 May)
• Melbourne (23-25 May)
gemacht.

Umsätze in Australien schon ganz gut,
nur bei uns lassen die Umsätze an manchen Tagen noch zu wünschen übrig,
wird sich aber ändern wenn der bekanntheitsgrad steigt.

Und man ist von anfang an dabei.

Gruß
ixilon

[realduke6]

Hallo ixilon,

wie komm ich denn zu den Umsaetzen von Australien,
wo werden die angezeigt.

Gruß realduke6

[ixilon]

@realduke6

http://stocknessmonster.com/
oder
http://www.asx.com.au

und dann Kürzel XBL eingeben

Gruß
ixilon

[ixilon]

22 June 2004

The Manager
Company Announcements
Australian Stock Exchange Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000


By e-lodgement


Dear Sir

We enclose a copy of an ASX Release titled “Polymerco changes name to PolyNovo Biomaterials Pty Ltd”

Yours sincerely

DAVID McAULIFFE
Chief Executive Office

________________________________________________________


22 June 2004

ASX / Media Release

POLYMERCO CHANGES NAME TO POLYNOVO BIOMATERIALS PTY LTD

Xceed Biotechnology Ltd (“Xceed”) is pleased to announce Polymerco Pty Ltd (“Polymerco”) has changed its name to PolyNovo Biomaterials Pty Ltd.

PolyNovo Biomaterials Pty Ltd is an operating subsidiary of Xceed that has acquired a license to a revolutionary biodegradable polyurethane technology from CSIRO with potential applications in orthopaedics, wound repair, drug delivery and stents.

Dr Ian Griffiths, (CEO PolyNovo), said ‘The company has decided upon a change of name as we move to position the company as a world leader in the field of biodegradable polymer chemistry.’

-ENDS-

Released by:

David McAuliffe
Chief Executive Officer
[phone]


Quelle : http://www.xceedbiotech.com/images/xceed-9-1-xaizu.pdf

[ixilon]

1 July 2004

The Manager
Company Announcements
Australian Stock Exchange Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000


By e-lodgement


Dear Sir,

We enclose a copy of a ASX / Media Announcement titled “Appointment of Xceed Biotechnology Ltd Chairman and Company Secretary.”

Yours sincerely
DAVID McAULIFFE
Chief Executive Officer


__________________________________________________________



1 July 2004

ASX / MEDIA RELEASE

APPOINTMENT OF XCEED BIOTECHNOLOGY LIMITED CHAIRMAN & COMPANY SECRETARY

Xceed Biotechnology Limited (“Xceed” or “the Company”), today appointed Dr Michael Dalling, formerly Group General Manager – R&D of ASX-listed Nufarm Limited, as Chairman of the Company. Dr Dalling will replace current Chairman, Mr Karl Paganin.

Ms Narelle Lloyd, current Company Secretary of operating subsidiaries PolyNovo Biomaterials Pty Ltd and Boron Molecular Ltd will replace Mr Karl Paganin as Company Secretary of Xceed.

-ENDS-

For further information:
David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited
Tel: [phone]

[ixilon]

19 July 2004


The Manager
Company Announcements
Australian Stock Exchange Limited
Level 4, 20 Bridge Street
SYDNEY NSW 2000


By e-lodgement


Dear Sir,

We enclose a copy of an ASX / Media Announcement titled “PolyNovo Biomaterials forms
Research Alliance with Imperial College London, UK”.

Yours sincerely
DAVID McAULIFFE
Chief Executive Officer


_______________________________________________________


ASX / MEDIA RELEASE


PolyNovo Biomaterials forms Research Alliance with Imperial College London, UK


PolyNovo Biomaterials Pty Ltd (“PolyNovo”) is pleased to announce it has formed an alliance with Imperial College London, UK to further develop aspects of its novel polymer technology for bone repair.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo, said “We are delighted to be collaborating with such a prestigious academic group and look forward to the additional product benefits that may emerge”.

Dr Molly Stevens leading the research at Imperial College’s Department of Materials said ”We are very excited to explore the potential orthopaedic applications of the novel polymer technology. We believe that there is great potential for these new materials in the regeneration of complex hard tissues such as bone due to the optimised environment they provide for tissue formation”.

Consistently rated in the top three UK university institutions, Imperial College London is a world leading science-based university whose reputation for excellence in teaching and research attracts students (11,000) and staff (6,000) of the highest international quality. Innovative research at the College explores the interface between science, medicine, engineering and management and delivers practical solutions that enhance the quality of life and the environment - underpinned by a dynamic enterprise culture.

-ENDS-

For further information:

David McAuliffe
Chief Executive Officer
Xceed Biotechnology
Tel: [phone]
Mob: [phone]
[e-mail]

Molly M Stevens
Department of Materials
Imperial College London
[e-mail]

[ixilon]

[ixilon]

21.07.2004

Change of Director`s Interest Notice

Quelle: http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=265283

[ixilon]

22.07.2004

Change of Director`s Interest Notice

Quelle: http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=265360

[ixilon]

23.07.2004

Change of Director`s Interest Notice

Quelle: http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=265418

[ixilon]

27.07.2004

Change of Director`s Interest Notice

Quelle: http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=265623

[ixilon]

[ixilon]

30.07.2004

Commitments Test Entity - Fourth Quarter Report

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=265958

[nonnenkloster]

Kann mir das jemand erklären?

In Australien steht heute der Kurs bei 0,3 (-1,6%), in Frankfurt steht der Kurs bei 0,160 (+ 3,23%), in Berlin bei 0,130 (-21,21%) und in Stuttgart bei 0,155 (-3,12%). Welcher ist nun der „faire“ Wert? Gehandelt wurde heute in Deutschland bisher nicht. Wie kommen diese gewaltigen Unterschiede zustande?

[ixilon]

17.08.2004

Change of Director`s Interest Notice

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=267240

[ixilon]

PolyNovo Biomaterials Pty Ltd (PolyNovo) is an operating division of Xceed Biotechnology Ltd, an Australian Stock exchange listed company (ASX Code: XBL)

PolyNovo is focused on developing a range of biocompatible and biodegradable polymers that will be used in next generation medical devices across multiple therapeutic areas. The biocompatible and biodegradable polymers can be broadly classified into three groups:
1. Novel injectable systems that will facilitate minimal invasive surgical techniques;
2. A putty that can be surgically shaped prior to a simple `cure on demand` step; and
3. A range of thermoplastics which can be used in standard process operations, injection molding, extrusion, solution processing etc.
Within each material classification the mechanical performance, rate of degradation and the degradation products can be altered to suit the application environment.

The objectives of the business are around developing specific material formulations for key markets. The mechanical and biological studies undertaken so far demonstrate the useful nature of these materials as load bearing porous structures, delivery systems for cells and sensitive biological agents, drug delivery, cartilage repair and generally as a bio-adhesive.

Our operations are based in Melbourne, Australia, within the CSIRO campus. This facilitates access to equipment and an ability to collaborate with world-class scientists across multiple disciplines.

Quelle : http://www.polynovo.com/index.htm

[ixilon]

4:08 pm

Preliminary Final Report & Annual Report

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=268258

[ixilon]

02.09.2004 2:05 pm

Change of Director`s Interest Notice

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=268511

[ixilon]

02.09.2004 3:40 pm

Change of Director`s Interest Notice

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=268531

[ixilon]

[ixilon]

Mending bones with ‘people glue’

June 2003

IF a toy breaks, the simple solution is often to glue it back together. So could the same principle be applied to a person who factures a bone?

A group of Australian scientists not only believe “people glue” would work but they are investing millions of dollars in the hope that it will become widely adopted as a standard medical procedure.

The glue – a biodegradable polymer – has been developed in a laboratory of the CSIRO’s Molecular Science division.

According to a CSIRO media statement, it would work by gluing a bone back together, providing structural support while the bone healed and then it would slowly degrade to leave only natural tissue in its place.

"Synthetic polymers offer a number of advantages over ceramic and natural polymer-based materials," said Dr Annabelle Duncan who heads the molecular division.

"We envisage that this polymer technology could be tailored for applications in orthopaedics, orthodontics, drug delivery, wound care, tissue engineering and cartilage repair."

Dr Thilak Gunatillake, one of the scientists who invented the polymer, said he expected it would first be used to repair bone fractures where it could be injected as a glue gel.

He said further research was now planned to demonstrate the polymer`s ability to deliver cells or biological agents to actually accelerate tissue regrowth.

"The use of the polymer for guided bone regrowth is not only applicable to the orthopaedic area, but also in related applications such as periodontal surgery and dental implants", Dr Gunatillake said.

To ensure the commercial development of the invention, CSIRO and Xceed Biotechnology have formed a joint company known as Polymerco Pty Ltd to further develop the concept.

As part of the arrangement, Xceed is investing more than $5 million on helping to develop the glue.


Quelle : http://www.scitech.org.au/sciencewa/current_stories/au/story…

[ixilon]

1 August 2004

Breakthrough Polymer For Bone Repair

When an object breaks, the simple solution is often to glue it back together again. So, why not people? A group of Australian scientists not only believe that “people glue” would work, but they are investing millions of dollars in the hope that it will become widely adopted as a standard medical procedure.


Contact: Dr. Thilak Gunatillake, Senior Principal Research Scientist

CSIRO Molecular Science, Bag 10, Clayton South VIC 3169

International Telephone: +61 3] 9545 2501 FAX: +61 3] 9545 2446

Email: [e-mail]

Contact: Dr. Ian Griffiths, CEO

Polynovo Biomaterials Pty Ltd, Bag 10, Bayview Ave., Clayton South MDC, VIC 3169

International Telephone: +61 3] 9545 2527 FAX: +61 3] 9545 8050

Email: [e-mail]

Website: http://www.polynovo.com


---------------------------------------------------------

TRANSCRIPT:

BLANCH: The glue – a biodegradable polymer – has been developed in a laboratory of the CSIRO’s Molecular Science Division. One of the polymer’s inventors is Dr Thilak Gunatillake. Thilak, this is a special kind of material that’s intended as a radical new treatment for people with broken bones, but what exactly is it intended to do?

GUNATILLAKE : This is synthetic polymer that is designed to break down inside the body and this polymer actually can be used as a glue to fix fractured bones, so we hope to actually further develop this technology so that, when people get broken bones, especially when you have multiple fractures, the glue--the product could be actually injected into the fracture site and the glue will actually set to a solid sort of porous structure, allowing the body to actually heal the fracture so, after some time when the fracture is healed, the polymer will break down and break down to harmless products and be removed from the body.

BLANCH : Yes, it gives it therefore support while it’s healing?

GUNATILLAKE : Yeah, this is one of the features of this new glue actually. We can formulate this glue so that it actually gives the strength so that during the healing process, not only provides the scaffold for the healing to occur while providing some mechanical strength to minimising perhaps the need for external support for a longer time.

BLANCH : It sounds to be a rather critical timing for when it breaks down?

GUNATILLAKE : Yes. We have sort of designed it so it will break down after about three or four months time, so generally for orthopaedic type applications that is sort of the timeframe when it requires for the bone to actually completely heal and retain the normal strength of the bone, so about three to four months time is what we expect the polymer to break down and, you know, disappear from the body.

BLANCH : Was that difficult to develop, that timing?

GUNATILLAKE : Yeah there is a fair bit of initial research work, perhaps about three to four year timeframe. We looked at various compounds and how to put them together so that it actually has the characteristic of the bio-compatibility - in other words that the material is non-toxic to the body and also designing the degradation characteristic – in other words the material actually degrades within the timeframe that is required for the application.

BLANCH : Well, it’s bio-degradable and bio-compatible and you touched on how the polymer is delivered to the site of the break, but have you finalised how it’s going to happen?

GUNATILLAKE : Well, we plan to actually for the next couple of years as part of the development plan, to actually further formulate and optimise the properties and also do further animal studies to make sure that we have the optimum formulation for that particular application.

BLANCH : What type of bone breaks do you think it will be best suited with this technology?

GUNATILLAKE : We believe that it can be used in any type of fracture – perhaps in a simple fracture it could be injected as a thin glue so that it holds the bone together. It also could be used in multiple fractures where you could actually, perhaps when there’s bone loss, this actually could be formulated to fill the gap that is created by some bone loss, so it could be used in a number of different applications. We believe it probably has advantages largely in areas where multiple fractures with bone loss, you know, the current technology requires using pins, screws and plates for the surgeon to actually put the bones back together, so we believe that this glue will have major applications in that area.

BLANCH : What do you believe are the advantages of synthetic polymers over ceramic and natural polymer-based materials?

GUNATILLAKE : Compared to natural polymers we can actually provide better mechanical strength and also, synthetic polymers, it allows you to actually design the material with the required final mechanical and other properties for the application. You don’t have the same flexibility with the natural polymers.

BLANCH : Well, to ensure the commercial development of the invention and to further develop the concept, CSIRO and Xceed Bio-technology have formed a joint company called PolyNovo of which Ian Griffiths is its CEO. So Ian, there are millions of dollars being invested in this technology, how will these initial dollars be spent, to achieve what?

GRIFFITHS : As Thilak said the development plan moving forward over the next 24 months or so is around formulating or optimising the formulations of these materials so that they can be proven in functional animal models, so the bulk of our expenditure moving forward is around resources and animal models to prove the usefulness of these materials.

BLANCH : This is said to be a platform technology, that is, a base from which other uses can be tailored, so in what disciplines would you expect other applications to be?

GRIFFITHS : We’ve discussed orthopaedics a little bit and the reason why we’re approaching the orthopaedic market first is because it plays into many of the advantageous novel strengths of this technology. However, in a broader context we believe it could be used as a surgical adhesive in certain applications in wound repair and also in terms of drug delivery and at the world bio-materials congress which happened in Sydney in May we actually had stunning interest from both academic groups and medical device companies particularly in the drug delivery space.

BLANCH : What about orthodontics?

GRIFFITHS : It’s a good question – orthodontics we believe naturally follows on from orthopaedics, so the technical solutions that are generated with the initial round of cash from Xceed will provide solutions which are equally applicable to orthodontics and reconstructive dental work.

BLANCH : Thilak, what’s the story of the development of the polymer, where did it start for you?

GUNATILLAKE : For quite a long time we have been working in the area of bio-materials trying to develop synthetic polymers for medical implants actually, so that technology matured and we now have a company actually commercialising that technology, so we’re looking at what other areas that we should work for as future technologies. So, tissue engineering was one area that has received interest from various research groups and industry, so we thought actually looking at this area we thought that there’s a need for new materials to use in tissue engineering type applications, so initial work was focused on this area actually trying to come up with materials that has all the demanding requirements for the tissue engineering application. That’s how we all started in this area first. The main approach we used was to actually design materials that are biodegradable and then from that we sort of targeted different applications and tried the technology if you could actually get the desired properties for this application.

GRIFFITHS : Could I add a point there too – I think the future of medical devices in many particular application areas is in terms of moving to a regeneration technology rather than a replace technology, so with our first applications we believe will prove the credibility of the technology platform, but as we move forward and the biological solutions around tissue engineering become more refined and commonplace, our technology will be ideally aligned as a delivery system for these biological solutions to regenerate tissue, both hard and soft.

BLANCH : What is the next stage of your research do you think Thilak?

GUNATILLAKE : Well, for the next couple of years actually I’ll be joining the polymer core research team and actually leading the research to do the development work and also I think looking at, as Ian mentioned, to explore this technology as a cell delivery method – in other words, that help the body to take the repair process, we’re trying to actually introduce cells and other components that support the cell growth, so we’ll be looking at that technology as the sort of next generation based on this platform technology.

BLANCH : And finally Ian, do you have a time line as yet for getting the first product to market?

GRIFFITHS : If all goes well, hopefully within about three to four years we’ll see the first clinical use of these technologies.

Quelle : http://www.abc.net.au/ra/innovations/stories/s1157049.htm

[ixilon]

20 September 2004

ASX / MEDIA RELEASE

Boron Molecular Expands into the USA with the recruitment of an Exclusive Agent

Boron Molecular Pty Ltd (“Boron Molecular”) is pleased to announce it has established a physical presence in the USA via the establishment of a USA agent, Boron Molecular Inc. The USA agency arrangement will allow Boron Molecular to further establish, promote and attempt to increase the sale and distribution of its unique range of organoboron compounds throughout the USA market.

Mr David McAuliffe said “As Boron Molecular currently generates in excess of 50% of its organoboron compound revenue from the USA market, we are very pleased to have been able to open an office in that territory via the recruitment of an exclusive agent. Mr Ken Sullivan, the newly appointed sales executive of Boron Molecular Inc, has significant experience in the organoboron compound sales sector and has proven to be a highly capable sales and marketing executive. It is envisaged that his already established network will grow Boron Molecular’s organoboron compound sales not only in the USA but also into Europe”.

Boron Molecular anticipates the agency agreement will provide access to a greater number of customers in the Company’s largest market and it is expected that a presence in the USA will further enhance the Company’s growing reputation in that territory as a provider of high quality, competitively priced organoboron products and services.

Boron Molecular Inc will officially commence operations on the 27th of September 2004.

-ENDS-

For further information:

David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited
Tel: [phone]

Ken Sullivan
Boron Molecular Inc
[e-mail]

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=269729

[ixilon]

21 September 2004

ASX / MEDIA RELEASE

PolyNovo Biomaterials advisor and collaborator named in Technology Review Magazine top 100 innovators

On 19 July 2004 Xceed Biotechnology Ltd announced PolyNovo Biomaterials Pty Ltd ("PolyNovo Biomaterials") had formed a Research Alliance with Imperial College London, UK.

PolyNovo Biomaterials is now pleased to announce that Dr Molly Stevens who leads the research at Imperial College`s Department of Materials has been nominated by Technology Review Magazine as one of the top new scientific explorers in the world.

Dr Stevens said "It`s very exciting and an honour for me to have the research recognised by the TR100."

TR100 is Technology Review Magazine’s list of 100 young people whose contributions to emerging technologies are poised to profoundly influence our world.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo Biomaterials said "We are delighted that Dr Stevens achievements have been recognised internationally and are extremely pleased to be working with her group at Imperial College London, UK".

Technology Review is a monthly magazine focusing on innovation and emerging technologies that have the potential to change the way we live and inclusion among the TR100 has become one of the most prestigious awards for young innovators around the world.

-ENDS-

For further information:
David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited
Tel: [phone]
Mob: [phone]
[e-mail]

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=269840

[ixilon]

24 September 2004 6:20 pm

Change in substantial holding

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=270171

[ixilon]

23 September 2004

ASX / MEDIA RELEASE

Boron Molecular Granted US & European Patent

Boron Molecular Pty Ltd (“Boron Molecular”) is pleased to announce it has been granted a US and European patent.

The patent is entitled Hydroboronation Process and has been issued with US patent number 6,680,401 and European patent number 1,127,060.

Dr Seb Marcuccio, Head of Research and Development at Boron Molecular said “We are very pleased to have this patent granted in the United States and Europe as this is a key patent for Boron Molecular. The protection granted by this patent allows Boron Molecular to generate a large number of new products of interest to the pharmaceutical and biotechnology industries.”

Quelle : http://www.xceedbiotech.com/images/xceed-18-1-cheyo.pdf

[ixilon]

[ixilon]

30 September 2004

Dear Shareholder

Xceed Biotechnology Ltd – Annual General Meeting

It is with great pleasure that I invite you to attend the first Annual General Meeting of Xceed Biotechnology Limited (“Xceed Biotechnology”).

Since listing on ASX on the 19th of May 2004, Xceed Biotechnology’s two investments, PolyNovo Biomaterials Pty Ltd (“PolyNovo Biomaterials”) and Boron Molecular Pty Ltd (“Boron Molecular”) continue to make excellent progress.

On the 20th of September 2004 Boron Molecular announced it had created a sales and marketing presence in the USA via the establishment of a USA agent, Boron Molecular Inc. The USA agency will allow Boron Molecular to further establish, promote and increase the sale and distribution of its unique range of organoboron compounds throughout the USA market.

PolyNovo Biomaterials, under the direction of the new Chief Executive Officer Dr Ian Griffiths, has realigned the original development programme of the company from orthopaedics and dental to now include orthopaedic and stent programmes.

Strategically this now provides PolyNovo Biomaterials with both medium and longer term development programmes and may allow the company to potentially have products in clinical trials in a shorter time frame.

Dr Griffith’s extensive contacts in the biomaterials field has allowed PolyNovo Biomaterials to
enter into collaborative alliances with Imperial College of London and Aortech Biomaterials Pty Ltd within weeks of the company’s start-up.

In addition, PolyNovo Biomaterials has entered into a material transfer agreement with an internationally recognised stent company and initiated preliminary animal studies. Other important on going animal studies continue to be conducted internally.

Clearly, the recruitment of Dr Griffiths with his demonstrated technical and commercial expertise, combined with his international licensing ability, has given PolyNovo Biomaterials tremendous momentum so quickly after startup.

As such when considering the Board’s request for shareholder approval for the issue of options to Dr Griffiths I would encourage shareholders to vote in favour of all the resolutions to ensure we are able to incentivise and retain Dr Griffiths.

In addition the company is also seeking shareholder approval for the issue of options to Non executive Directors and again I would encourage shareholders to vote in favour of all the resolutions to ensure we are able to attract and retain high calibre professions in the role of Non executive Director.

I look forward to keeping all shareholders updated on the progress we make over the next six months and thank all shareholders for their continuing support of the Board and Xceed Biotechnology.

Yours sincerely

Michael Dalling

Chairman

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=270960

[ixilon]

01.10.2004

Notice of Annual General Meeting

EXPLANATORY MEMORANDUM and PROXY FORM

2004 Annual General Meeting to be held at the Conference Room, Level 8, Exchange Plaza, 2 The Esplanade, Perth, Western Australia on Friday 26 November 2004 commencing at 11.30 am (WST)

Mehr Info : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=270961

[ixilon]

01.10.2004

Appendix 3B - Employee Options

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=270985

[ixilon]

08.10.2004

ASX / MEDIA RELEASE

PolyNovo Biomaterials positive outcome in initial mini-pig trial for coronary stent coatings

Life Science investment company Xceed Biotechnology Ltd is pleased to announce that one
of its major investee companies, PolyNovo Biomaterials Pty Ltd (“PolyNovo”), has conducted
mini-pig trials with an unnamed US based stent manufacturer on stent coatings.

Recently obtained histology data from the initial animal study provided positive results. This
is the first time that PolyNovo’s polymer has been evaluated as a stent coating in arterial
blood flow and represents a significant validation for potential use in stents. Just one
potential core application of PolyNovo’s polymer technology.

Coronary stents (“stents”) are small wire tubes that are implanted in blood vessels by
minimally invasive techniques. These tubes re-open vessels that have become blocked,
while the vessel wall grows back in an open position. These stents are commonly used as an
alternative to coronary artery bypass surgery, but are also widely used in other blood flow and
non-blood flow situations.

The stent industry is estimated to be US$ 2.6 billion dollars. Although currently available
stents and drug eluting stents are revolutionary treatments, there is considerable
development activity in new stent technology to reduce the likelihood of vessel re-blockage
after the stent has been placed.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo commented "We believe that the next
generation stent products will increasingly use biodegradable materials. The combination of
mechanical properties suitable for stent delivery and tailored degradation times make our
polymers potentially ideal for future stent coatings and whole stent development."

-ENDS-

For further information:

Mr David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited
Tel: [phone]

Dr Ian Griffiths
Chief Executive Officer
PolyNovo Biomaterials Pty Ltd
Tel: [phone]

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=271452

[ixilon]

PolyNovo conducts stent trial: Xceed

Source: MELBOURNE AAP
Date: 2004-Oct-08 02:13 PM

Life sciences investor Xceed Biotechnology Ltd said that one of the companies in which it invests, PolyNovo Biomaterials Pty Ltd, had conducted a successful animal trial on stent coatings with a United States stent manufacturer.

Coronary stents are small wire tubes that are implanted in blood vessels to re-open vessels that are blocked, while the vessel wall grows back in an open position.

PolyNovo is developing biocompatible and biodegradable polymers that promote tissue growth and which can be used as stent coatings.

PolyNovo chief executive officer Dr Ian Griffiths said an initial animal study using mini-pigs had yielded positive results.

"This is the first time that the PolyNovo polymer has been evaluated as a stent coating in arterial blood flow and represents a significant validation for potential use in stents," Dr Griffiths said.

"We believe that the next generation stent products will increasingly use biodegradable materials.

"The combination of mechanical properties suitable for stent delivery and tailored degradation times make our polymers potentially ideal for future stent coatings and whole stent development."

Quelle : http://www.tradingroom.com.au/news_research/index.jsp?page=a…

[ixilon]

[ixilon]

20.10.2004 11:25 am

PolyNovo Biomaterials in research alliance with the Bionic Ear Institute.

Life Science investment company Xceed Biotechnology Ltd is pleased to announce that one of its major investee company’s, PolyNovo Biomaterials Pty Ltd (“PolyNovo”), has formed a research alliance with the Bionic Ear Institute that may potentially lead to the development of new devices for nerve regeneration.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo, said, “We are excited to have this opportunity to work with this world-renowned institute with a great track record. We have already established encouraging data on cell growth through complex polymer scaffolds in our degradable materials. Using feedback from Institute scientists, we will tailor our proprietary materials to enable them to take the next steps.”

Research to regenerate nerves requires a greater understanding of the adherence of nerves to polymers, the method of incorporating nerve growth factors into the polymers, the effect of the release of the nerve growth factors, and the role of adult stem cells in nerve growth along the scaffold created by the polymer.

Institute director and Bionic Ear pioneer, Professor Graeme Clark, said, “PolyNovo`s novel polymer technology would appear to provide significant advantages over conventional biodegradable polymers in this area. I am confident that this opportunity to work with industry may provide the breakthroughs we need for next generation nerve repair devices.”

-ENDS-

For further information:
David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited
Tel: [phone]

Dr Ian Griffiths
Chief Executive Officer
PolyNovo Biomaterials Pty Ltd
Tel: [phone]

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=272339

[ixilon]

Bionic Ear Institute

The Bionic Ear Institute is home to some of Australia’s finest scientists and research staff. Established in 1983, it is an independent, non-profit, medical research organisation. It’s aims are to give deaf children and adults the opportunity to participate as fully as possible in the hearing world and to find new ways to restore brain function.

Based in Melbourne, the Institute has an international reputation for scientific rigour and research excellence. Bionic Ear research began in the late 1960s at The University of Melbourne and this important relationship continues with the many of its staff working alongside Department of Otolaryngology researchers. The Institute is formally affiliated to the University.

A close working relationship with the Cochlear Implant Clinic means the Institute has ongoing contact with surgeons, audiologists and other hearing professionals as well as Bionic Ear users themselves. This means it is in constant contact with people who can give immediate feedback on the research based on their personal experience. Other strengths include the strong multidisciplinary team, a track record of successful spin-off companies, freedom from commercial constraints and our overriding commitment to patient safety and wellbeing. The Institute values collaborations with other leading research organisations both in Australia and overseas. The Bionic Ear Institute is Managing Agent for the Co-operative Research Centre for Cochlear Implant and Hearing Aid Innovation and accredited by the NHMRC as an independent research institute.

[ixilon]

20.10.2004 4:41pm

Appendix 3B - New issue announcement, application for quotation of additional securities and agreement

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=272389

[nonnenkloster]

In Australien ist nach der Veröffentlichung des 1. Quartalsergebnisses heute der Kurs auf 0.33 AUD (+ 1.5%) gestiegen. Das entspräche einem Kurs von 0.193 Euro in Deutschland. Und was macht Berlin?? 0.15 (-18.72%)

[ixilon]

22 October 2004


Quarterly Report for the three months ending 30 September 2004


Xceed Biotechnology Ltd - Corporate

This is Xceed Biotechnology Ltd’s (“Xceed Biotechnology”) first quarterly report to the Australian Stock Exchange since its successful listing in May 2004.

Since listing Xceed Biotechnology has recorded a number of significant achievements both at a corporate level and within its investee companies.

At the corporate level Dr Michael Dalling has been appointed as Chairman to the Board of Xceed Biotechnology.

Ms Narelle Lloyd has been appointed as Chief Financial Officer and Company Secretary of Xceed Biotechnology and its investee companies.

The cashflow used in operations for business development, financial management, compliance and public company administration was $129k for the first quarter of the financial year

Xceed Biotechnology’s first Annual General Meeting will be held at 11.30am on the 26 November 2004 at Level 8 Exchange Plaza, 2 The Esplanade Perth Western Australia.



PolyNovo Biomaterials Pty Ltd

Since it officially began operations on 1 July 2004 PolyNovo Biomaterials Pty Ltd (PolyNovo), has made significant progress with both its research and development plan and entry into commercial and strategic alliances.

PolyNovo is developing a injectable, biodegradable and biocompatible polymer platform technology with potential application in orthopaedics, stents, drug delivery, wound care, orthodontics, tissue engineering and cartilage repair.

The various commercial and strategic alliances signed to date will assist PolyNovo in the commercialisation of its polymer technology. They are:

Facilities and Access Agreement with CSIRO

PolyNovo has negotiated a two year agreement to locate its research and development activities at the CSIRO Division of Molecular Science’s Ian Wark Laboratories in Clayton, Victoria, with an option to extend for a further year.

Alliance with Aortech Biomaterials

PolyNovo and AorTech Biomaterials (“Aortech”) have entered into an agreement under which PolyNovo’s novel biodegradable polyurethane technology will be scaled-up, stabilised and manufactured at AorTech’s ISO certified Melbourne Australia Technology Centre.

Research Alliance with Imperial College London, UK

PolyNovo has formed an alliance with Imperial College London, UK to further develop aspects of its novel polymer technology for use in bone repair activities.

Initial mini-pig trial for coronary stent coatings delivers positive outcome

Recently obtained histology data from the initial animal study involving pigs provided positive results. This is the first time that PolyNovo’s polymer has been evaluated in arterial blood flow and represents a significant validation for potential utilisation in stent manufacture.

Research alliance with the Bionic Ear Institute.

At the start of the new quarter Polynovo announced a research alliance with the Bionic Ear Institute in Melbourne that may potentially lead to the development of new devices for nerve regeneration.

Along with PolyNovo’s solid progress in its research and development programme, the company was also able to keep cash outflow from its operations of $186k significantly under budget for the first quarter.



Boron Molecular Pty Ltd

During the quarter Boron Molecular continued increasing its catalogue of available organoboron compounds, which now stands at more than 400.

Organoboron compounds are used by the global pharmaceutical and biotechnology industries for that facilitate the synthesis and scale up of potential drug candidates.

Sales of compounds sales increased by approximately 10% in the first quarter of 2005 compared to the previous quarter. The continuing sales growth is due to several factors including, the increasing range of compounds available, increasing numbers of customers and increasing quantities being purchased by customers.

Further significant sales growth is expected to result from the appointment of an Exclusive Agent in the United States, which was announced at the end of the quarter.

Recruitment of an Exclusive Agent

Boron Molecular Inc has been established in the USA as the exclusive sales agent for Boron Molecular. The USA agency arrangement allows Boron Molecular to further establish, promote and increase the sale and distribution of its unique range of organoboron compounds throughout the USA market.

US & European Patent Granted

During the quarter Boron Molecular was granted US and European patents. The patents are entitled Hydroboronation Process and Boron Molecular has been issued with US patent number 6,680,401 and European patent number 1,127,060.

Boron Molecular’s EBITDA for the first quarter was a loss of $129k. Earnings performance is expected to improve with anticipated increased revenues. Boron Molecular’s cash outflow from operations was $31k for the first quarter.

-ENDS-

For further information:
David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited
Tel: [phone]

Quelle : http://www.xceedbiotech.com/images/xceed-24-1-eibee.pdf

[ixilon]

[ixilon]

Ferret`s Stock to Watch: XCEED BIOTECHNOLOGY LIMITED
08:20, Tuesday, 26 October 2004

A BIOTECH COMPANY PUTTING THE RUNS ON THE BOARD


Sydney - Tuesday - October 26: (RWE)
************************************
OVERVIEW
********
Xceed Biotechnology Ltd has so far been a good investment for its
shareholders who were lucky enough to score a bundle back in May when the
company floated to the public.
The shares were issued at 20c and this month are trading between
31 and 33c.
What is rather curious is that Xceed has a web site and its
wholly owned subsidiary Boron Molecular also has one of its own as if it
was a separate entity.
It must be said that the Boron web site is much more user
friendly than its parent Xceed.
It may well have occurred before the two came together as a
public company.
But in any case Boron is on the ball and moving along nicely
with significant promise.
Boron Molecular Pty Ltd is a chemistry company providing leading
pharmaceutical and biotech companies with small molecules to enhance
their drug discovery programs.
Boron Molecular`s proprietary chemistry expertise is in the
creation of organoboron compounds that facilitate the synthesis and scale
up of potential drug candidates.
The company offers organoboron and coupled compounds, provides
custom synthesis and toll manufacture, leading to partnerships with
companies in drug discovery and development.
Meanwhile last week Xceed Biotechnology reported its first
quarterly results to the ASX since listing in May 2004.
Since listing Xceed Biotechnology has recorded a number of
significant achievements both at a corporate level and within its
investee companies.
At the corporate level Dr Michael Dalling has been appointed as
chairman to the Board of Xceed Biotechnology.
Ms Narelle Lloyd has been appointed as chief financial officer
and company Secretary of Xceed Biotechnology and its investee companies.
The cashflow used in operations for business development,
financial management, compliance and public company administration was
$129k for the first quarter of the financial year.
Directors said PolyNovo Biomaterials Pty Ltd (PolyNovo), has made
significant progress with both its research and development plan and
entry into commercial and strategic alliances.
The company is developing a injectable, biodegradable and
biocompatible polymer platform technology with potential application in
orthopaedics, stents, drug delivery, wound care, orthodontics, tissue
engineering and cartilage repair.
The various commercial and strategic alliances signed to date
will assist PolyNovo in the commercialisation of its polymer technology.
These include facilities and Access Agreement with CSIRO.
PolyNovo has negotiated a two year agreement to locate its
research and development activities at the CSIRO Division of Molecular
Science`s Ian Wark Laboratories in Clayton, Victoria, with an option to
extend for a further year.
Alliance with Aortech Biomaterials PolyNovo and AorTech
Biomaterials ("Aortech") have entered into an agreement under which
PolyNovo`s novel biodegradable polyurethane technology will be scaled-up,
stabilised and manufactured at AorTech`s ISO certified Melbourne
Australia Technology Centre. -
PolyNovo Biomaterials Pty Ltd has forged a research alliance
with Imperial College London, UK to further develop aspects of its novel
polymer technology for use in bone repair activities.
Initial mini-pig trial for coronary stent coatings delivers
positive outcome Recently obtained histology data from the initial animal
study involving pigs provided positive results.
This is the first time that PolyNovo’s polymer has been evaluated
in arterial blood flow and represents a significant validation for
potential utilisation in stent manufacture.
At the start of the new quarter Polynovo announced a research
alliance with the Bionic Ear Institute in Melbourne that may potentially
lead to the development of new devices for nerve regeneration.
Along with PolyNovo`s solid progress in its research and
development program, the company was also able to keep cash outflow from
its operations of $186k significantly under budget for the first quarter.
SHARE PRICE MOVEMENTS
*********************
Xceed shares yesterday closed steady at 33c. Rolling high to date
has been 34.3 cents and low 20.3c.
During the quarter Boron Molecular continued increasing its
catalogue of available organoboron compounds, which now stands at more
than 400.
Organoboron compounds are used by the global pharmaceutical and
biotechnology industries for that facilitate the synthesis and scale up
of potential drug candidates.
Sales of compounds sales increased by approximately 10 per cent
in the first quarter of 2005 compared to the previous quarter.
The continuing sales growth is due to several factors including,
the increasing range of compounds available, increasing numbers of
customers and increasing quantities being purchased by customers.
Further significant sales growth is expected to result from the
appointment of an Exclusive Agent in the United States, which was
announced at the end of the quarter.
Recruitment of an Exclusive Agent Boron Molecular Inc has been
established in the USA as the exclusive sales agent for Boron Molecular.
The USA agency arrangement allows Boron Molecular to further
establish, promote and increase the sale and distribution of its unique
range of organoboron compounds throughout the USA market.
During the period under review, Boron Molecular was granted US
and European patents.
The patents are entitled Hydroboronation Process and Boron
Molecular has been issued with US patent number 6,680,401 and European
patent number 1,127,060.
Boron Molecular`s EBITDA for the first quarter was a loss of
$129k.
Earnings performance is expected to improve with anticipated
increased revenues.
Boron Molecular`s cash outflow from operations was $31k for the
first quarter.
BACKGROUND
**********
Xceed Biotechnology is a biotechology investment company that
made its debut on the Australian Stock Exchange on May 19,2004.
It focuses on investment in revenue producing and research based
leading edge patentable technologies.
Xceed currently has two core assets in its portfolio, a 50 per
cent stake in Polynovo Biomaterials pty and 100 per cent interest in
Boron Molecular pty.
The core technologies of each company has been developed by the
CSIRO.
Xceed`s investment in the life sciences sector include a
$5.1 million investment into PolyNovo Biomaterls with the retention of 50
per cent equity ownership and the acquisition of 100 per cent of Boron
Molecular.
The company will initially focus on the development and
commercialisation of Polynovo Biomaterials` novel biodegradable polymers
and increase the sales of Boron Molecular range of products and
collaborative partners.
Xceed Biotechnology`s first annual general meeting will be held
at 11.30am on November 26, in Perth, Western Australia.
Boron Molecular background
***************************
Boron Molecular Pty Ltd was formed in 2001 to develop and
commercialise novel organoboron technology invented and developed by the
Commonwealth Scientific and Industrial Research Organization, Molecular
Science (CSIRO) in Australia.
The current range of products and services include: organoboron
compounds, Suzuki coupled compounds, intermediates, custom synthesis and
chemistry services.
Boron Molecular dedicated chemistry and support staff operate
from well-equipped facilities in Melbourne, Australia.
Boron Molecular`s skilled team of chemists has expertise in the
design of syntheses of milligram to multi-kilogram quantities of
compounds.
The laboratory facilities and full-time personnel are versatile
in performing research and development of the organoboron product
portfolio or synthesizing challenging custom molecules or undertaking
contract chemistry service work.
Boron Molecular`s core skills not only include boron chemistry,
but also medicinal chemistry (including nucleoside chemistry), scale-up,
discovery, development, and commercialisation.
In addition, Boron has established a successful track record of
servicing multi-national pharmaceutical companies.

[nonnenkloster]

@ixilon,

danke für die Info. Mal wieder ein sehr übersichtlicher Artikel, der alles auf den Punkt bringt. Der ist also am Dienstag erschienen, ich verstehe jetzt...

[der_loser]

hallo leute,

kann mal kurz einer die news auf deutsch zusammenfassen, danke.

[ixilon]

Listed Biotechnology Companies in 2003 and 2004

Valutech tracks over 100 listed companies in Australia which carry out biotechnology-related activities. This link provides a snapshot of the industry.

The following information has been obtained from Valutech databases and the comments offered reflect the views of the company. These views are not based on whether we regard certain stock as worth investing from a speculative point of view. Rather, they represent our assessment as to whether there is technical and commercial substance in the companies reviewed. For investment advice, we recommend that investment analysis reports be studied and potential investors reach their own views.

In the first nine months of 2004, the overall trend remains one of lethargy and disinterest with most stocks remaining level or drifting down and a move to the more established companies which have recorded increases of 10% or more. There seems to be a strong movement away from the speculative stocks to the security of the more established stocks. We have also noted two significant gaps developing between the stocks valued at less than $120 million, stocks valued around $160-180 million and those more than $200 million as a result of the shift to the more secure companies.

Notable developments have been the merger talks between Peptech and Agenix (discontinued ), the entry of BresaGen into voluntary administration, the mergers with US companies (Benitec, Chemgenix, Gradipore), the sale of Axon and the push by other companies such as Australian Cancer into the US market and the mass of floats that have taken place including Australis Aquaculture, Avastra, Biosignal, Biopharmica, Cygenics, Living Cell Technologies, Bone, Xceed Biotech, Regenera, Genepharm, Avexa, Sunshine Heart, Acrux and Proteome Systems.

Of the more expensive stocks, Progen has tripled in price, and Cellestis is up 100% based on expectations of future sales in the US and Japan and Psivida is up 85%. There have also been recoveries in CSL (up 60%) and significant improvements for Circadian, Metabolic and Nufarm. Significant falls occurred with Chemeq (50%), Sirtex (40%), Novogen (40%) and Unitract (35%) associated with a dawning shareholder perception of reality.

Of the midrange stocks, new entried did well with Australia up 70%, Bone up 75% and Living Cell up 80%. Other improvers were Anadis up 60%, Epitan up 30%, Pharmaxis up 85% and Virax up 50%. Significant falls of more than 30% occurred with Agenix, BioDiem, Cytopia, Genesis R&D (50%), Norwood Abbey (50%), Peplin, Polartechnics (50%) and newly listed Proteome Systems.

For the cheaper stocks, only 5 out of 46 increased.. Increases occurred with Australian Cancer (70%), BioPharmica (15%), Iatia (up 30%), Imugene (25%) and Xceed (40%). Falls of 40% or more occurred with AVT (60%), Cogstate (50%), Clover (50%), Eiffel (50%), EQiTX (50%), Environmental Solutions (70%), Genesis Biomed (50%), Medigard (55%), PanBio (40%), Prima Biomed (55%), Rockeby (70%), Solagran (40%) and Visiomed (40%).

During 2003, there were significant movements in stock values. The first half of the year was relatively unremarkable with many speculative biotechnology stocks drifting down and only the more solid stocks or interesting stocks going against this trend.

In the period June through to around August, there was a considerable upturn in interest in biotechnology related stocks and the overall index was reported to have increased by some 80% in that period, significantly more than the NASDAQ biotechnology index. Since that time, stocks have either levelled off or drifted down unless there were issues of substance which were able to continue the upward trend in stock prices.

Quelle : http://www.valutech.com.au/pages/Biotech2003.html

----------------------------------------------------------

XBL - Xceed Biotechnology Ltd.

Relisting of a broadband communications company as a biotechnology investment vehicle. This company has taken 100% of Boron Molecular and has 50% of a joint venture with CSIRO developing biopolymers. It is too early at this stage to comment on the company. However, it is cashed up and has small turnover with low losses so prices can be expected to remain relatively stable in the short term. (14/10/04)

Quelle : http://www.valutech.com.au/pages/Biotech2003RV.html

[der_loser]

hallo ixilon,

finde ich super deine beitraege in englisch.
wie waere es mal mit einer uebersetzung ins deutsche, oder liegt das nicht in deiner macht???

[ixilon]

Online-Übersetzer

http://babel.altavista.com/tr

[ixilon]

3.11.2004 1:21pm

Change of Director`s Interest Notice

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=274198

[ixilon]

11.11.2004 2:08pm

Change of Director`s Interest Notice

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=274748

[ixilon]

[ixilon]

24.11.2004 1:11pm

Change of Director`s Interest Notice

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=275842

[ixilon]

[ixilon]

26.11.2004

Results of AGM

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=276258

[ixilon]

26.11.2004

Appendix 3B

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=276260

[ixilon]

29.11.2004

Change of Director`s Interest Notice

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=276378

[ixilon]

29.11.2004

Change of Director`s Interest Notice

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=276380

[ixilon]

29.11.2004

2004 AGM Presentation

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=276493

[ixilon]

2.12.2004 12:50 pm

Boron Molecular granted USA Patent

ASX / MEDIA RELEASE

Boron Molecular Granted USA Patent Life Science investment company Xceed Biotechnology Ltd is pleased to announce that one of its investee company’s, Boron Molecular Pty Ltd (“Boron Molecular”), has been granted a USA patent.

The patent is entitled Substituted Diboron Compounds and has been issued with USA patent number 6,794,529.

Dr Seb Marcuccio, Head of Research and Development at Boron Molecular said “We are very pleased to have this patent granted in the United States as this patent compliments other patents that have been granted in this territory.”

-ENDS-

For further information:
David McAuliffe
Xceed Biotechnology Limited
[e-mail]
Tel: [phone]

Dr Seb Marcuccio
Boron Molecular Pty Ltd
[e-mail]
Tel: [phone]

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=277025

[ixilon]

07.12.2004

Change of Director`s Interest Notice

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=277510

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=277511

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=277527

[ixilon]

5.01.2005 8:30 am

ASX / MEDIA RELEASE

PolyNovo Biomaterials to undertake Australian Animal Trials of its polymer

Life Science investment company Xceed Biotechnology Ltd (“Xceed”) is pleased to announce that its major investee company, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) will shortly commence the company’s first animal trial in sheep with orthopaedic grades of its unique polymer.

PolyNovo has secured the animals, raw materials, ethics approval and independent external trial design verification. The trial will be conducted at one of Australia’s leading large-animal surgical facilities.

PolyNovo’s key scientists are currently finalising the manufacturing of polymers for the study. These orthopaedic grades of the polymer will have compressive properties that are similar to bone and will be studied in a variety of solid and porous forms.

The trial is designed to confirm the potential superiority and safety of PolyNovo’s polymers for a range of orthopaedic applications over a series of time-points up to 6 months. In addition, PolyNovo expects to obtain further data confirming the polymers ability to significantly enhance fracture fixation in healthy and potentially osteoporotic patients.

Chief Executive Officer, Dr Ian Griffiths, indicated that undertaking this extensive animal trial will be a significant achievement for PolyNovo which recently commenced operations in July 2004.

PolyNovo will advise on further progress relating to this trial and other animal trials it may undertake during 2005.

For further information concerning PolyNovo, please visit the company website at www.polynovo.com.

-ENDS-

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=279386

[Strassenlampe]

14 January 2005

Boron Molecular presence at Informex in USA

Xceed Biotechnology Ltd (“Xceed”) is pleased to advise that one of its investee companies, Boron Molecular Pty Ltd (“Boron Molecular”), will be present at the worlds leading fine chemical conference in the USA commencing on 17 January 2005.
Boron Molecular will be represented by its exclusive USA agent, Boron Molecular Inc, and its principal, Mr Ken Sullivan.
For over 20 years, the Informex conferences have been the leading industry event for the fine chemical industry, with over 450 exhibitors and 4000 attendees expected in 2005.
Since it’s recent establishment Boron Molecular Inc has been actively pursuing its sales and marketing strategy in the USA. Extensive marketing of Boron Molecular’s available range of organoboron compounds and chemistry services has been carried out, including the distribution of a sales product list to in excess of 6,000 USA based chemists.
Mr David McAuliffe, Chief Executive Officer of Xceed said “We are very pleased to again be attending the Informex conference having just recently established a presence in the USA.
This conference will allow us to continue the promotion of Boron Molecular’s USA agent, further developing existing relationships and expanding it’s customer base and networks in the USA for Boron Molecular’s range of products and services.”

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=279920

[ixilon]

28th

Commitments Test Entity - Second Quarter Report

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=280907

[ixilon]

28th

Quarterly Cash Flow Commentary

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=280911

[ixilon]

[ixilon]

8 February 2005

ASX / MEDIA RELEASE

PolyNovo to undertake feasibility studies with the Burns Unit at Royal Adelaide Hospital

Xceed Biotechnology Ltd (“Xceed”) is pleased to advise that its major investee company, PolyNovo Biomaterials Pty Ltd (“PolyNovo”), has aligned itself with the Burns Unit at Royal Adelaide Hospital to investigate the feasibility of utilising NovoSorb, its biodegradable polymer technology, in conjunction with the Burns Unit cell biology for the treatment of burns.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo stated “ We are hopeful that NovoSorb will provide advantages over the existing materials used for tissue scaffolds in the treatment of burns.”

PolyNovo will be working closely with Mr John Greenwood AM and his team. Mr Greenwood is currently the Director of the Burns Unit at the Royal Adelaide Hospital and played a key role in providing life saving operations on the burns victims following the 2002 Bali attack.

Mr Greenwood stated “The challenge facing clinicians and scientists in replacing lost skin is recreation of the supple, elastic and robust dermis. This is an architectural structure which needs the clinician to recruit the help of engineers. This alliance brings together specialists from different fields approaching the problem of dermal generation from different directions. I am extremely excited at this prospect."

-ENDS-

For further information:
David McAuliffe
Chief Executive Officer
Xceed Biotechnology Limited
Tel: [phone]

Dr Ian Griffiths
Chief Executive Officer
PolyNovo Biomaterials Pty Ltd
Tel: [phone]

About Xceed Biotechnology Ltd (www.xceedbiotech.com)
Xceed Biotechnology Ltd (Xceed) is a biotechnology investment company that made its debut on the Australian Stock Exchange (ASX:XBL) on 19 May 2004. Xceed will focus on investment in revenue producing and research-based leading-edge patentable technologies. Xceed currently has two core assets in its portfolio, 50% of PolyNovo Biomaterials Pty Ltd (PolyNovo) and 100% of Boron Molecular Pty Ltd (Boron), with the core technologies of each company having been developed by CSIRO. Broadly, Xceed will initially focus on: - the development and commercialisation of PolyNovo’s novel polymers; and - increasing the sales of Boron’s range of products and collaborative partners.

PolyNovo Biomaterials Pty Ltd (www.polynovo.com) PolyNovo Biomaterials Pty Ltd (PolyNovo) was established in May 2004 by CSIRO and Xceed Biotechnology Ltd, which each own 50 percent of the Company. It is focused on developing a range of biocompatible and biodegradable polymers that can be formulated as an injectable gel which cures in-situ or on demand, promotes tissue growth and controls the rate of degradation. PolyNovo`s technology is based on novel, patentable chemistry developed within the CSIRO’s Division of Molecular Science and licensed to the company under a worldwide exclusive royalty free license. The polymer technology could be tailored for applications in orthopaedics, stents, drug delivery, wound care, orthodontics, tissue engineering and cartilage repair.

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=281923

[ixilon]

14 February 2005

ASX / MEDIA RELEASE

PolyNovo signs with Large International Medical Device Company in the field of Stents and Stent Coatings

Life Science investment company Xceed Biotechnology Ltd (“Xceed”) is pleased to announce
that its major investee company, PolyNovo Biomaterials Pty Ltd (“PolyNovo”) has entered into
an agreement with a large international medical device company in the field of stent coatings
and fully biodegradable stents.

Stents are minimally invasive devices that re-open vessels that have become blocked, while
the vessel restructures. Stents are commonly used as an alternative to coronary artery
bypass surgery, but are also widely used in other blood flow and non-blood flow situations.

The stent industry is estimated to be US$ 3 billion dollars per year. Although currently
available stents and drug eluting stents are revolutionary treatments, there is considerable
development in new stent technology to reduce the likelihood of vessel reblockage.

The Agreement provides for studies of various grades of NovoSorb, PolyNovo’s polymer
technology, that are considered most suitable for potential stent applications.

In addition the companies have entered into a period of exclusive negotiation for codevelopment
programs. If suitable terms are met these programs could lead to partnerships
or licence agreements to develop next generation stent products.

As with all negotiations there is no certainty that the parties will be able to reach agreement
but each company has committed to the process.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo said “A combination of NovoSorb’s
mechanical properties, degradation times and process options, opens a wide range of
possibilities for new innovations in stent technology.”

Mr David McAuliffe, Chief Executive Officer of Xceed said “PolyNovo’s ability to be able to
attract a partner of such size and international standing is a validation not only of the
company’s strategy in this field, but also of the potential of the technology into which Xceed
has invested.”

Xceed looks forward to keeping all shareholders updated on the progress PolyNovo makes
over the coming months.

-ENDS

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=282237

[ixilon]

2 Jahreschart

[ixilon]

16.02.05

CEO Contract not to be renewed

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=282441

----------------------------------------------------------

16.02.05

Final Director`s Interest Notice

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=282460

----------------------------------------------------------

16.02.05

Change of Director`s Interest Notice

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=282475

[ixilon]

28.02.05

Half Yearly Report

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=283541

----------------------------------------------------------

28.02.05

Half Year Audit Review

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=283558

----------------------------------------------------------

28.02.05

Company Secretary Appointment

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=283630

[ixilon]

01.03.05

Change of Director`s Interest Notice

http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=283786

[ixilon]

[ixilon]

Financial Review Insert - 15 February 2005

AFR Article - Super Glue for plastic people - Polymers may ease the pain of broken bones

While it is notoriously difficult to define a living organism, biochemists have added an oddly pragmatic point of view to the complex metaphysics: organisms are little more than an inspired amalgamation of a rather dull class of molecules – polymers.

In a physical sense, these are long and very repetitive molecules; long chains built by linking simple building blocks end on end. But the class includes the likes of DNA and proteins that have high information content. However, while defining a human in this way would never satisfy the philosophers, the polymer approach does come with interesting medical ramifications.

In fact, two of the issues that concern hospital patients the most – the invasiveness of a procedure and disability during recuperation – could each be improved considerably by going the polymer route. Dr Thilak Gunatillake, at CSIRO’s

Molecular Science division, explained the situation with regards to a broken bone. According to scientists, the metallic pins and screws currently in use by surgeons have a number of drawbacks. Especially designed, synthetic and biodegradable polymers may provide a better option.

The goal is to reach into the body with little more than a syringe and needle containing a liquid gel (NovoSorb). Applied at the fracture, the gel cures into a polymer that glues the fractured bone together and mechanically supports it while the polymer aids and abets the healing process.

Rather than needing follow-up surgery to remove pins, the polymer is designed to naturally degrade at a rate that coincides with healing.

Each of these properties – reduced invasiveness, curing from a liquid to a polymer form, mechanical strength, recruitment of cells that aid healing, biodegradability – is made possible because they are intrinsic to the design of a polymer from the polyurethane family.

Despite very promising results in animal trials, it is generally a long way from a lab discovery to a clinically available medical procedure. However, thanks to an innovative CSIRO commercialisation program, Dr Gunatillake and his team will not have to sacrifice their lab work to make that journey.

While the scientists pursue the design of novel polymers, over the past year CSIRO has invested the intellectual property in a start-up company called PolyNovo Biomaterials. In May 2004, Xceed, an Australian Stock Exchange (XBL) listed biotechnology investment company, supplied $5.1 million in exchange for 50 percent of PolyNovo equity.

With these funds, PolyNovo is actively overseeing product development. Executive Officer Dr Ian Griffiths explained this as a three-stage process. First PolyNovo hopes to start co-developing devices using NovoSorb in conjunction with medical device companies. Then the pre-clinical trial will determine product safety. Full clinical trials are then required to assess product efficacy. If all goes well, PolyNovo’s first product could receive market approval in three to five years.

The development of a fully biodegradable stent is of high priority in PolyNovo’s product development plan. “A certain percentage of heart patients experience re-blockage of the coronary artery following the insertion of a stent,” explained Dr Griffiths.

While coating stents with antiinflammatory agents is useful, PolyNovo is “designing materials suitable for a device that keeps the vessel open, and once remodelling and natural healing occurs in two to three months, the stent is re-absorbed and degraded”.

In contrast, the bone-fracture orthopaedic polymer is about 18 months behind the stent in the commercialisation process.

There is also a third variation for use in surgical situations. Cured by the use of blue light, these polymers can fill gaps in more complex fractures.

However, the story does not end there. Tissue engineering, wound care and drug delivery are further examples of medical procedures that could hitch a ride on PolyNovo’s polymer technology.

Dr Ian Griffiths
Chief Executive Officer
PolyNovo Biomaterials Pty Ltd
Tel: [phone]

[ixilon]

MELBOURNE FIRM PROVIDES CENTREPIECE FOR NEW $6M BIONICS CENTRE

A Melbourne biotechnology company with a novel biodegradable plastic has joined
forces with other market leaders to fast track development of next generation bionics
technologies.

PolyNovo Biomaterials Pty Ltd, and its novel plastic material called NovoSorb, is one of
the key technologies to be applied and commercialised in a range of medical devices by
VicBionics – a new $6 million centre announced by the Victorian Government’s Science
Technology and Innovation program. PolyNovo is a subsidiary of Xceed Biotechnology
Ltd, a listed life sciences investment company.

Dr Michael Dalling, Chairman and Acting Managing Director of Xceed, said the new
Centre would “support and boost Victoria’s strategic objective to be one of the top five
biotechnology locations in the world by 2010.”

VicBionics will focus its efforts initially on developing new coatings that will reduce the
risk of infection from pacemakers, joints and other implantable devices; systems for early
treatment of epileptic seizures and nerve and spinal cord repair.

“Australia already supplies more than 60% of the global demand for bionic ears,” said
Prof Graeme Clark, head of the famed Bionic Ear Institute and partner in the new centre.
“The challenge for VicBionics is to build on this expertise to create a new generation of
medical bionic devices and get them to market.”

Other partners in VicBionics include St Vincents Hospital Centre for Neurosciences and
Neurological Research and CSIRO’s Molecular Sciences and Textile Fibre Technology
divisions and Intelligent Polymer Research Institute at the University of Wollongong.

Dr Ian Griffiths, PolyNovo’s CEO, said “NovoSorb is a unique family of biodegradable
plastics that we can customise for different biological applications. We can make them
soft to match body tissues or hard – to match with bone. And we can control the speed
at which these plastics biodegrade – from months to years. As the plastic biodegrades,
it can slowly release active compounds – such as growth factors or anti-microbials – just
where they are needed.”

He added that PolyNovo will provide the key technology platform to develop new ways to
improve nerve and spinal cord repair. “With only about 5% of current neural repair
procedures achieving satisfactory results, and with an estimated 2.5 million people
worldwide living with spinal cord injury, it’s important that a concerted approach be made
to find novel ways of solving these complex problems,” he said.

For more information, contact: Dr Michael Dalling on 0408 141 934 or Dr Ian Griffiths on
[phone].

www.xceedbiotech.com
www.polynovo.com.au

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=287352

[ixilon]

3 Jahreschart

[ixilon]

26.04.05

[URLChange of Director`s Interest Notice]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=288163[/URL]

[ixilon]

29.04.05

[URLCommitments Test Entity - Third Quarter Report]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=288666[/URL]

[ixilon]

[ixilon]

06.05.2005

[URLAppoints CEO for Boron Molecular]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=289407[/URL]

[ixilon]

06.05.2005

[URLAppoints Non-Executive Director]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=289408[/URL]

[ixilon]

06.05.2005

[URLInitial Director`s Interest Notice]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=289410[/URL]

[ixilon]

17,05,2005

[URLChange of Director`s Interest Notice]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=290081[/URL]

[ixilon]

17,05,2005

POLYNOVO BIOMATERIALS, CSIRO AND ITRI ENTER COLLABORATIVE
AGREEMENTS TO FURTHER DEVELOP POLYMER DELIVERY AND TISSUE
ENGINEERING SOLUTIONS FOR CARTILAGE REPAIR

Dr Michael Dalling, Chairman and Acting CEO of Life Science investment company Xceed
Biotechnology Limited today announced that one of its investee companies, PolyNovo
Biomaterials Pty Ltd (“PolyNovo”), has entered into collaborative agreements with the
Commonwealth and Scientific Industrial Research Organisation (“CSIRO”) and Industrial
Research Institute of Taiwan (“ITRI”) that are focussed on the development of new tissue
engineering solutions for cartilage repair. If this collaboration is successful it is the intention
of PolyNovo, CSIRO and ITRI to commercialise the resulting technology through the
establishment of a spin out company.

Whilst knee injury during sport receive the most publicity, each year millions of people
globally injure their knee cartilage. All suffer pain, economic loss, lifestyle restrictions and
often proceed to osteoarthritis.

Under this program PolyNovo’s unique polymer (NovoSorb) will be used to deliver novel
cell therapy technology, developed by ITRI and CSIRO, to the injury site through a minimally
invasive procedure. The cell therapy will repair the injury while NovoSorb functions
mechanically in the knee allowing patient mobility. Once the repair / re-growth is complete
NovoSorb will harmlessly degrade. If successful this will represent a significant breakthrough
in the treatment of cartilage injury. The global market for these products is estimated to be
$2.5 billion US.

Dr Ian Griffiths, Chief Executive Officer of PolyNovo said “A combination of CSIRO and ITRI’s
cell biology technologies and our novel polymers have the potential to overcome many of the
limitations of current technologies utilised for cartilage repair. Our aim over the next twelve
months is to advance the combined approach to the point of undertaking additional animal
studies as a lead into human clinical trials. ”

Dr Dalling said this development is an important endorsement of the wide potential of
PolyNovo’s NovoSorb technology platform and further strengthens the continuing close
working relationship between CSIRO and the Xceed investee companies”.

CSIRO is one of the world’s largest and most diverse scientific research organisations.
CSIRO has approximately 6500 staff working across Australia.

Dr Annabelle Duncan , Chief of CSIRO Division of Molecular Science said:

`` CSIRO and ITRI have jointly developed a novel cell biology technology that, with further
development, we hope will be suitable for use with PolyNovo`s biodegradable polymers.
CSIRO is pleased to be able to continue to work with PolyNovo Biomaterials Ltd, a company
that was spun -out of CSIRO in 2004.``

Founded in 1973, ITRI is a non-profit R&D organization that has helped guide the
technological and economic growth of Taiwan. ITRI has incubated world-class technologies in
semiconductors, personal computers, and many other high-tech sectors of Taiwan. Over the
years, ITRI has facilitated the creation of over 200 start-up companies and received over
6,000 patents. The 6000 people operation include seven laboratories and four centres which
focus on five major areas: biomedical technologies, information and communication; material,
chemical and nanotechnologies; advanced manufacturing and systems. Backed by its broad
research scope and close industrial ties, ITRI is an active member in the global industrial
R&D community


Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=290118

[ixilon]

18.05.2005

[URLChange of Director`s Interest Notice]
http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=290225[/url]

[ixilon]

30.05.2005

[URLHeader Correction: Options Cancelled]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=290944[/URL]

[ixilon]

01.06.2005

[URLAppendix 3B - New Issue]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=291169[/URL]

[ixilon]

XBL - Xceed Biotechnology Ltd.

Relisting of a broadband communications company as a biotechnology investment vehicle. This company has taken 100% of Boron Molecular and has 50% of a joint venture with CSIRO developing biopolymers. It is too early at this stage to comment on the company. However, it is cashed up and has small turnover with low losses but prices have dropped 26% in 2005 and are now just below the relisting price which is good in a difficult environment. (24/5/05)

Quelle : http://www.valutech.com.au/pages/Biotech2005RX.html

[ixilon]

.

[URLKey investment information - shareanalysis.com]http://www.shareanalysis.com/ASP/Search/PageRedirect.asp?SecId=XBL[/URL]

.

[ixilon]

03.06.2005

[URLXceed Appointments]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=291423[/URL]

[ixilon]

09.06.2005

[URLCancellation of Options]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=291642[/URL]

[ixilon]

10.06.2005

[URLFinal Director`s Interest Notice]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=291739[/URL]

[ixilon]

6 Monatschart



Gruß
ixilon

[ixilon]

16.06.2005

[URLEmployee Share Option Scheme - update]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=292119[/URL]

[ixilon]

23.06.2005

[URLCompany Secretary Appointment]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=292493[/URL]

[ixilon]

24.06.2005

[URLAppointment of CEO]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=292570[/URL]

[ixilon]

3 Monatschart



Gruß
ixilon

[ixilon]

.

Feasibility Studies and Exclusive Negotiation Period with
Large International Medical Device Company Extended

20 July, 2005

On 14 February 2005, Xceed Biotechnology Ltd (Xceed) announced that its
investee company, PolyNovo Biomaterials Pty Ltd (PolyNovo), had “entered
into an agreement with a large international medical device company in the
field of stent coatings and fully biodegradable stents.” The agreement
provided for the conduct of collaborative feasibility studies aimed at
determining the suitability of NovoSorbTM, PolyNovo’s polymer technology, in
coated and full stent applications.
The agreement also provided for an exclusive period of six months for the
negotiation of a co-development program which could include partnering or
licensing arrangements aimed at developing next generation stent products.
PolyNovo has advised that the joint feasibility studies are progressing well and
as a result both parties have agreed to an extension of the exclusive period
for the negotiation of a co-development program for a further 3 months.
As previously advised the outcomes of such negotiations are highly
unpredictable and there can be no guarantee of arriving at mutually
acceptable terms nor can there be any certainty of timeframe for a conclusion
to be reached.
Xceed will provide shareholders with updates on the progress of negotiations
over the coming months as events allow.

Further Information:
David Kenley
CEO
Xceed Biotechnology Ltd
Tel: [phone]

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=294357

Gruß
ixilon

[ixilon]

Der Frankfurter Chart

3 Monate

[ixilon]

20.07.2005

[URLChange of Registered Office]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=294369[/URL]

[ixilon]

29.07.2005

[URLCommitments Test Entity - Fourth Quarter Report]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=295417[/URL]

[ixilon]

1 Jahreschart

[ixilon]

08.08.2005

[URLAppt of CEO as Director/Initial Directors Interest Notice]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=296185[/URL]

Gruß
ixilon

[ixilon]

13.09.2005

[URLFinancial Results for the Year Ended 30/06/05]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=298887[/URL]

Gruß
ixilon

[ixilon]

24.10.2005

[URLAnnual Report 2005]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=302848[/URL]

[ixilon]

24.10.2005

[URLNotice of Annual General Meeting]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=302850[/URL]

Gruß
ixilon

[mai2000]

@ixilon

gibts auch ´nen kleinen Kommentar von dir?

[ixilon]

2005 Chart


6 Monatschart


Hallo mai2000,

viel Geduld braucht man bei Xceed, glaube aber das die Bodenbildung bald abgeschlossen ist.
Was jetzt fehlt ist mal eine News die Fantasie in den Wert bringt.

Gruß
ixilon

[mai2000]

... ach übrigens, wollte vorher noch danke sagen fürs Reinstellen.

[ixilon]

28.10.2005

[URLCommitments Test Entity - First Quarter Report]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=303817[/URL]

[ixilon]

.

NovoSorb Scientists win CSIRO Research Achievement Medal

17 November, 2005

Xceed Biotechnology Limited (Xceed) is pleased to announce that the
scientific team of its major investee company, PolyNovo Biomaterials Pty Ltd
(PolyNovo), which invented and continues to technically enhance its
NovoSorb™ technology has been awarded the 2005 CSIRO Research
Achievement Medal. This medal honours CSIRO’s most significant
achievement for the year in the field of research.
The NovoSorb™ technology encompasses a family of novel biodegradable
polymers which are internationally attracting substantial commercial interest
for application in next generation medical devices. The PolyNovo team is
currently focusing the majority of its efforts on developing innovative products
for the treatment of diseases in the cardio vascular and orthopaedic fields.
The team is now working on a raft of commercial applications of NovoSorb™
including the development of an injectable gel and a fully biodegradable stent.
The gel aims to assist with the fixation of complex bone fractures, while the
biodegradable stent will help restore blood floor in blocked arteries without the
need for a permanent implant device.
This award recognises the significant scientific achievements of PolyNovo’s
scientists in generating technologies and products with the potential to be
successfully commercialised in global healthcare markets.
...

Quelle : http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=305786

Gruß
ixilon

[ixilon]

.

[URLAnnual General Meeting Presentation 24 November, 2005]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=306585[/URL]

Gruß
ixilon

[ixilon]

24 November, 2005

[URLResults of Annual General Meeting]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=306663[/URL]

[ixilon]

6 12.2005

[URLUpdate on Cartilage Repair Project]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=308060[/URL]

Gruß
ixilon

[ixilon]

Wünsche ein ruhiges, besinnliches Weihnachtsfest
und alles Gute für 2006.

Liebe Grüße von ixilon

[ixilon]

23.12.2005

[URLAppendix 3B]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=310041[/URL]

[ixilon]

23.12.2005

[URLChange of Director`s Interest Notice]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=310044[/URL]

[ixilon]

3 Jahreschart

[ixilon]

6 Monatschart

[ixilon]

24.01.2006

[URLTrading Halt]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=311861[/URL]

[ixilon]

24.01.2006

[URLPolyNovo announces a Global Partnering Deal]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=311898[/URL]

[ixilon]

24.01.2006

[URLPresentation on global partnering deal]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=311899[/URL]

[ixilon]

31.01.2006

[URLCommitments Test Entity - Second Quarter Report]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=312534[/URL]

[ixilon]

01.02.2006

[URLFinancial performanceofBoron Molecular significantlyimproved]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=312982[/URL]

[ixilon]

06.02.2006

[URLCorporate Presentation February 2006]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=313313[/URL]

[ixilon]

09.02.2006

[URLPolyNovo Biomaterials presents at Biomaterials Conference]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=313627[/URL]

[ixilon]

13.02.2006

[URLRepair Technology Reported in CSIRO Solve Magazine]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=313855[/URL]

[ixilon]

HEALTH TECHNOLOGIES:
Joint Effort Proves Promising

By Whitney MacDonald

A pairing of cellular and polymer technologies could soon be used to repair the damaged knees of thousands of Australians.

A characteristically Australian trait is the love of sport. Unfortunately, this love affair with activity often comes at a painful price, with more than a million sports-related injuries occurring each year, 12 per cent of them involving the knee joint. Current knee injury treatment options can provide some relief, but they have limitations.

However, in a scientific joint venture, local researchers are pairing cellular and polymer technologies to create future treatment options.

One component of the knee joint particularly prone to damage is the cartilage, comprised of the shock-absorbing menisci, that sit in between the femur and tibia, and the articular cartilage, a thick covering at the end of the knee bones that minimises damage to them by providing a near frictionless surface on which the bones can slide.

Severe damage to the cartilage might require a total knee replacement. The short life expectancy of the replaced joint – generally 10 to 15 years – makes it an unfavourable option for a young person likely to need multiple replacements in the course of their life.

Alternatively, a patient may receive autologous chondrocyte implantation (ACI); that is, injection of healthy cartilage-forming cells, taken from an undamaged site in the patient’s body, which have been expanded before being injected into the damaged site. However, this treatment does not allow any mechanical support, so that the patient must spend several weeks on crutches.

A better option is now under development. A joint research team, comprised of scientists from CSIRO Molecular and Health Technologies, the Industrial and Technology Research Institute of Taiwan (ITRI), and PolyNovo Biomaterials Pty Ltd – a subsidiary company of Xceed Biotechnologies Ltd – is developing a superior tissue-engineering technology to treat damaged cartilage.

By drawing on both the biological and chemical expertise within the team, researchers have devised a two-pronged approach to treating an injured knee.

The first component uses proprietary cellular techniques to grow a large number of healthy chondrocytes for ACI in a short time, about 10 days. By using a combination of growth supplements, bead matrices and optimised cell densities in a bioreactor, culturing conditions promote rapid growth of chondrocytes, while still maintaining their cartilage-specific cell type – an aspect that has proven difficult with current ACI methods.

To complement the cellular treatment of damaged cartilage, the second prong of the technology incorporates the patented polymer system NovoSorb™, a novel biodegradable polymer designed for use in human medical devices. Specially optimised grades are being tailored to act as synthetic scaffolding to offer support and stability to a recovering knee joint. The uncured polymer is mixed with expanded healthy cells from a person’s body, and then injected into the site of damaged cartilage using arthroscopy (keyhole surgery).

Dr Charles Lindall, who leads the commercialisation of this project at CSIRO, says the strength of the product comes from combining the biological and chemical technologies to offer patients and surgeons a more comprehensive treatment option.

“NovoSorb™ provides the initial repair and support, while the cells slowly start to regenerate and become functional tissue,” he says. “The polymer is non-toxic to the cells and porous, allowing the necessary exchange of nutrients for cell viability.

“Once the cells have reached a functional level, the polymer slowly degrades, leaving the newly generated cartilage to resume its normal role of stabilising the knee joint.”

The new technology will speed the treatment procedure in both the surgery and the recovery phases.

“The proprietary cell culturing technology enables us to reduce the time needed to expand the healthy chondrocytes from many weeks to a mere 10 days, allowing the injured patient to begin treatment sooner,” Dr Lindall says.

The collaboration’s goal is to reduce the surgery time from 90 minutes to about 30 minutes with the arthroscopic delivery of cells mixed with NovoSorb™ polymer. “We are aiming for a speedier recovery, too. Because NovoSorb™ should provide almost immediate stability in the joint, we anticipate the patient will walk out of the hospital the next day without crutches.”

While the polymer-cellular technology has only been developed in the past year and a half, the results in animal models look promising, with clinical trials expected to be carried out over the next three years. This time will also serve as a patent-finalising and capital-raising period, before a market launch. In addition, the team will ultimately be considering forming a spin-off company and/or a partnership with a larger company.

“Although our initial market is patients with knee injuries, this technology has applications for other injured joints as well as degenerative damage to tissue,” he says. “The current medical trend is about teaching the body how to heal itself, rather than having totally synthetic materials in the body and never regenerating its own natural tissue.”

With a global market of more than $2 billion for cartilage repair, this is one trend that is not likely to go out of style.

Quelle : http://www.solve.csiro.au/0206/article2.htm

[ixilon]

3 Monatschart



Netter Anstieg bei hohem Volumen

Gruß
ixilon

[ixilon]

[ixilon]

[doktor7]

[posting]20.247.670 von ixilon am 17.02.06 01:43:12[/posting]mensch ixilon,

is ja ein Ding. Da hat mal jemand eine Aktie ganz
für sich alleine. Oder fast.

Glückwunsch, Du hast es verdient!

[ixilon]

Mensch doktor7,

ich hoffe aber dass Du ab und zu mal reinschaust, damit ich hier nicht ganz so alleine bin.

Gruß
ixilon

[ixilon]

14.02.2006

[URLChange of Director`s Interest Notice]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=313969[/URL]

[ixilon]

15.03.2006

[URLHalf Yearly Report & Half Year Accounts]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=316731[/URL]

Gruß
ixilon

[ixilon]

16.03.2006

[URLCEO`s Letter to Shareholders]http://stocknessmonster.com/news-item?S=XBL&E=ASX&N=316989[/URL]

[ixilon]

1 Jahreschart



Gruß
ixilon

[bobolo]

Hi ixilon,
super Deine Informationen. Ich bin seit frag mich nicht wie lange schon - damals noch Southpoint - investiert und halte zur Zeit noch 23001 Anteile und hab eigentlich nicht mehr geglaubt, daß sich noch was tut mir der Company. Werde jedoch vermehrt wieder darauf achten und ggf. meinen Anteil aufstocken.
Danke nochmal für Deinen guten Service.

[ixilon]

PolyNovo Biomaterials presents at 2006 Annual Meeting of the Society of Biomaterials in the US

MELBOURNE, Australia, 26 April 2006: Xceed Biotechnology Ltd (Xceed) (ASX: XBL):

Dr Roshan Mayadunne and Dr Raju Adhikari, Senior Research Scientists of Xceed subsidiary PolyNovo Biomaterials Pty Ltd, will present this week at the Annual Meeting of the Society of Biomaterials in Pittsburg, USA (program and details available at http://www.biomaterials.com).

The Society for Biomaterials provides the world’s leading forum for the introduction and dissemination of knowledge for developments in the field of biomaterials. This meeting is attended by most of the leading US based medical device manufacturers.

The presentations give an overview of the latest data on grades of NovoSorb designed for orthopedic applications. Preliminary results from various time points of the major animal study (refer previous ASX announcement dated 5 January 2005) are discussed. These polymers are candidates for next generation spinal repair and orthopedic applications which have now become a major commercial focus for PolyNovo.

Further Information:
David Kenley, CEO, Xceed Biotechnology Ltd
Email: [e-mail], Tel: [phone]

Ian Griffiths, CEO, PolyNovo Biomaterials Pty Ltd
Email: [e-mail], Tel [phone]


Hallo bobolo,

mach ich doch gerne

Gruß
ixilon

[ixilon]

28.04.2006

[URLCommitments Test Entity - Third Quarter Report]http://sa.iguana2.com/cache/b07c571c0d8f4b1eeeab851a9e52d0c8/ASX-XBL-321056.pdf[/URL]

[ixilon]

05.05.2006

[URLRelease of Securities from Escrow]http://sa.iguana2.com/cache/4dcb05798a7c8941f3c4049a7e30d766/ASX-XBL-322166.pdf[/URL]

[ixilon]

.



Quelle : http://sa.iguana2.com/cache/3a07d6cc5ba08090fe612a176907764e…

[ixilon]

6 Monatschart



......Februar GAP geschlossen und MACD, Stoch. im überverkauften Bereich

Gruß
ixilon

[ixilon]

NovoSorb wins Future Materials Award

18 May, 2006

Xceed Biotechnology Limited (Xceed) is pleased to announce that the PolyNovo Biomaterials Pty Ltd (PolyNovo), NovoSorb™ technology was a Judge’s finalist and won the peoples choice award at the 2006 Excellence in Materials Innovation in Biotechnology and Life Sciences award by Future Materials.
Future Materials is a Commonwealth government endorsed not-for-profit national organisation supported by a consortium of leading Universities. Future Materials aims to help Australian companies gain a competitive advantage by enhancing industry access to materials technologies within universities and other research institutions.
The NovoSorb™ technology encompasses a family of novel biodegradable polymers which have attracted substantial international interest for application in next generation medical devices. The PolyNovo team is currently focusing on developing the biodegradeable stent technology in collaboration with Medtronic, Inc. Other areas of focus include the development of innovative products for the treatment of diseases in the orthopaedic and wounds management fields.
This award was received by Drs Adhikari and Mayadunne who, together with Dr Gunatillake invented NovoSorb™. It recognises the scientific achievements of PolyNovo’s scientists in generating technologies and products with the potential to be successfully commercialised in global healthcare markets.

Further Information:
David Kenley
CEO
Xceed Biotechnology Ltd
Tel: [phone]
...

www.xceedbiotech.com
www.polynovo.com

Quelle : http://sa.iguana2.com/cache/f9eac0f2e2380b8cc7a96273efbbedfe…

[ixilon]

26.05.2006

[URLAppendix 3B]http://sa.iguana2.com/cache/2cf690db6e134afbfc738d30f48772d1/ASX-XBL-324140.pdf[/URL]

[ixilon]

.

Monday, June 12, 2006, 8:21AM AEST - The Australian Stockmarket is closed for Queen\'s Birthday

Gruß
ixilon

.

[ixilon]

09.06.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/ebb554c0fea7d01a9af2aae10a531fa5/ASX-XBL-325457.pdf[/URL]

13.06.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/a7b3b34d4ac5a4b19e0b2ff7fc3f7690/ASX-XBL-325607.pdf[/URL]

15.06.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/81c5a986c394c6584fc98b62d938230c/ASX-XBL-325820.pdf[/URL]

15.06.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/e13935cf70c185b54e73129570f6439a/ASX-XBL-325848.pdf[/URL]

[ixilon]

19.06.2006

[URLPolyNovo forms J V for Next Generation Wounds Products]http://sa.iguana2.com/cache/42f9fb6b3d9a04bf491d3f4f29008b5e/ASX-XBL-326091.pdf[/URL]
.

[ixilon]

20.06.2006

[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/4a2a80ff2db5d3226252c1a863d8bccf/ASX-XBL-326148.pdf[/URL]

[ixilon]

27.06.2006

[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/0bc32c304c026ca7a457f2772e046f77/ASX-XBL-326669.pdf[/URL]

[david1]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[ixilon]

10.07.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/8595ddfec22423c4dabdd2fa4c87a7ba/ASX-XBL-327909.pdf[/URL]

10.07.2006
[URLBecoming a substantial holder]http://sa.iguana2.com/cache/0812791b6e96c52ceb381aa79521e66c/ASX-XBL-327910.pdf[/URL]

10.07.2006
[URLCeasing to be a substantial holder]http://sa.iguana2.com/cache/5e0cf600bce098b70b86aaf7d5a686a7/ASX-XBL-327911.pdf[/URL]

[ixilon]

18.07.2006

[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/1e10f92d85b8b8d384b85bd4fccae7e2/ASX-XBL-328601.pdf[/URL]

[ixilon]

20.07.2006

[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/1f8f0474e1657ad3fd2d48d713364b68/ASX-XBL-328784.pdf[/URL]

[ixilon]

WA Business News

O’Connor lifts stake in Xceed Biotech

27-July-06
Written by Colin Jacoby
Xceed Biotechnology Ltd non-executive chairman Patrick O’Connor is continuing to buy up the company, bringing the value of his stake to more than $2 million.

Quelle :http://www.wabusinessnews.com.au/login_google.php?url=http%3…

[ixilon]

28.07.2006

[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/a78627bf71256fe7c284aa29b4bacce7/ASX-XBL-329638.pdf[/URL]

[ixilon]

28.07.2006

[URLCommitments Test Entity - Fourth Quarter Report]http://sa.iguana2.com/cache/c6339da3d7c977e7aaf33ea3602363fd/ASX-XBL-329736.pdf[/URL]

[ixilon]

2 Monatschart

[der_loser]

Antwort auf Beitrag Nr.: 23.291.425 von ixilon am 03.08.06 01:38:45

@ ixilon, deine beiträge sind so super.

[ixilon]

PolyNovo forms collaboration with Stem Cell Centre

28 July, 2006

Xceed Biotechnology Limited (ASX:XBL) (‘Xceed’) is pleased to announce that its 60% owned subsidiary company, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’) has today signed an agreement with the Monash University Immunology and Stem Cell Laboratories (MISCL). The agreement provides for MISCL to test the utility of NovoSorb™ as a potential scaffold for stem cells.
The studies will provide important data about the potential to deliver stem cells utilizing pre-formed NovoSorb™ scaffolds. This data will complement the positive data already obtained through collaboration with CSIRO, using cartilage cells, and Royal Adelaide Hospital with various skin cell lines.
If the studies are successful the parties aim to extend the study to focus on the potential of utilizing stem cells in a range of next generation therapies. Including possible applications in the field of regenerative medicine.
The Monash Immunology Stem Cell Laboratories (MISCL) harbor Monash University's world renowned research in stem cell science, with an emphasis on embryonic stem cells and their potential applications in the repair and regeneration of blood, pancreatic, respiratory, renal and neural tissues. The centre has an international reputation in immunology, stem cells and tissue repair, and is closely allied to the Australian Stem Cell Centre and other Monash departments focusing on development, genomic and epigenetic science, reproduction, immunology and transplantation medicine. MISCL has more than 40 honors and postgraduate research students demonstrating a commitment to training the next generation of stem cell scientists. MISCL is a centre of research excellence within the School of Biomedical Sciences, in the Faculty of Medicine, Nursing and Health Sciences at Monash and attracts competitive research support from national and international public institutions and commercial partnerships. The centre attracts many overseas visitors and nucleates research collaborations involving a broad range of Monash scientists.

Quelle : http://sa.iguana2.com/cache/f629a76281834a01c4e3f47168e12158…

[ixilon]

02.08.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/0647b2a64675248013a95707871e6fb1/ASX-XBL-330489.pdf[/URL]

04.08.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/17de1b42ae9c7112dd68726c3d2c3036/ASX-XBL-330667.pdf[/URL]

10.08.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/1cf816c9874facf38820278bccc964c1/ASX-XBL-331110.pdf[/URL]

17.08.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/3a70fad845401e3c9b43fddb62be108a/ASX-XBL-331691.pdf[/URL]

[ixilon]

3 Jahreschart

[ixilon]

17.08.2006

[URLChange in substantial holding]http://sa.iguana2.com/cache/ffc05ded049a3f4df35617284b08266e/ASX-XBL-331692.pdf[/URL]

[ixilon]

22.08.2006

[URLBoron's strong financial turnaround results in profit]http://sa.iguana2.com/cache/2ed4411a69f827dbfbe6579588e2128f/ASX-XBL-332005.pdf[/URL]

[ixilon]

Sehr hohes Volumen heute

Frankfurt 0,125€ +7,76% 675.483 Stck

[ixilon]

25.08.2006

[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/742a21a5b3417cc7f220a6a1e5edb001/ASX-XBL-332362.pdf[/URL]

[ixilon]

05.09.2006

[URLPolyNovo reports positive data from Sheep Trial]http://sa.iguana2.com/cache/326398d9717b8652ee791ed5ba8573fa/ASX-XBL-333232.pdf[/URL]

[ixilon]

NovoSkin’s Partner Receives TGA Licence

6 September, 2006
Xceed Biotechnology Limited (ASX:XBL) (‘Xceed’) is pleased to advise that the Skin Engineering Laboratory, founded by NovoSkin’s Clinical Director Dr John Greenwood, has just been accredited by the Therapeutics Goods Administration (TGA) as the first Australian laboratory capable of producing cultured skin cell products.

On 19 June 2006, Xceed announced that its 60% owned subsidiary company, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’) had established a joint venture company (‘NovoSkin’) with eminent Adelaide burns surgeon, Dr John Greenwood AM.

NovoSkin’s focus is to develop a range of innovative skin regeneration products. Dr Greenwood’s Skin Engineering Laboratory will carry out critical biological activities for the NovoSkin product development.

PolyNovo’s CEO, Dr Ian Griffiths, said “To be the first in Australia to receive this accreditation from the TGA shows clearly the quality and capability of John and his team. My confidence is further increased that NovoSkin will be successful in its product development aims. The joint venture now has enhanced capability to build value, particularly in our innovative skin regeneration matrix product, the Bioresorbable Temporising Matrix (BTM), for use in the treatment of severe burns.”

Dr John Greenwood said “The decision by the TGA reflects an enormous effort by Amy Li and Bronwyn Dearman the senior scientists of the Royal Adelaide Hospital’s Skin Engineering Laboratory. Their regulatory design and execution of facility management will have direct benefits to patients today and will accelerate the advanced skin engineering research currently underway with NovoSkin”.
...

Quelle : http://sa.iguana2.com/cache/63dddc0e4188cbbd45d59b456051fd85…

[ixilon]

13.09.2006

[URLPreliminary Final Report]http://sa.iguana2.com/cache/3af64fb578cd2b549770058811f3a068/ASX-XBL-334253.pdf[/URL]

Gruß
ixilon

[ixilon]

3 Monatschart

[ixilon]

14.09.2006

[URL[B}Change of Director's Interest Notice[/B]]http://sa.iguana2.com/cache/cd7b0343f71321f46f04e997a3d861cf/ASX-XBL-334393.pdf[/URL]

[ixilon]

15.09.2006

[URLAmended Change of Director's Interest Notice]http://sa.iguana2.com/cache/769021eb860372a3607513adc428603c/ASX-XBL-334553.pdf[/URL]

[ixilon]

18.09.2006

[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/56cc7e37f7eef63f6b74231e10d72ca3/ASX-XBL-334674.pdf[/URL]

[ixilon]

20.09.2006

[URLCollaboration with Bionic Technologies Aust & Cochlear]http://sa.iguana2.com/cache/4306afd8a582da7cddd0197947b5f2d5/ASX-XBL-334874.pdf[/URL]

[ixilon]

22.09.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/ffdece57c301f26f50e5858d31d44ea6/ASX-XBL-335116.pdf[/URL]

25.09.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/99749322daaa4634492268a9ecd53966/ASX-XBL-335316.pdf[/URL]

[ixilon]

27.09.2006

[URLChange in substantial holding]http://sa.iguana2.com/cache/0b6013cbd3763bd7e2f0ea022003c25a/ASX-XBL-335654.pdf[/URL]

[ixilon]

29.09.2006

[URLFinancial Report for the year ended 30 June 2006]http://sa.iguana2.com/cache/633f3310c0e5fc21ff42e8af5260da59/ASX-XBL-336137.pdf[/URL]

[lottojan10]

mensch ypsilon,

du machst dir echt mühe

grüße

lotto

[ixilon]

29.09.2006

[URLFull Year Audit Review]http://sa.iguana2.com/cache/d8b30637805ac25c4172e9e49f150a6a/ASX-XBL-336138.pdf[/URL]


Hallo lottojan10,

mach ich doch gerne

Gruß
i(yps)xilon

[ixilon]

29.09.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/74eee16a4ad4b2c6f40b832bbef7316c/ASX-XBL-336163.pdf[/URL]

03.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/369c7f5e69f1bdae9f477e70138b51c8/ASX-XBL-336509.pdf[/URL]

12.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/99c974870a64c7d509ea1f024a11edab/ASX-XBL-337483.pdf[/URL]

16.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/4dcd96de95a6f8242daaabea7de338f2/ASX-XBL-337835.pdf[/URL]

19.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/2e683834131dbcadc6d64168f27ab8e4/ASX-XBL-338296.pdf[/URL]

[ixilon]

23.10.2006

[URLCommitments Test Entity - First Quarter Report]http://sa.iguana2.com/cache/cf050c93ba2b2fabfe7d134ec0f7ac70/ASX-XBL-338521.pdf[/URL]

[ixilon]

24.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/83de2a725003db2b8d5fa8eaebeea150/ASX-XBL-338675.pdf[/URL]

27.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/ae0670024304b5ef83e5c3389e81413f/ASX-XBL-339403.pdf[/URL]

31.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/b553d3b3b8f7d00e184f6914c2d71609/ASX-XBL-340098.pdf[/URL]

[ixilon]

26.10.2006

[URLNotice of Annual General Meeting]http://sa.iguana2.com/cache/be9d7ee8945d636d595afe0baee32927/ASX-XBL-339087.pdf[/URL]

[ixilon]

2 Jahreschart

[ixilon]

26.10.2006

[urlAnnual Report]http://sa.iguana2.com/cache/647f3fabb06858fc6aceeab52fb19f1c/ASX-XBL-339103.pdf[/url]

[ixilon]

XBL 0.270 AUS-Dollar +10.2%

[ixilon]

27.10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/ae0670024304b5ef83e5c3389e81413f/ASX-XBL-339403.pdf[/URL]

31 10.2006
[URLChange of Director's Interest Notice]http://sa.iguana2.com/cache/b553d3b3b8f7d00e184f6914c2d71609/ASX-XBL-340098.pdf[/URL]

[ixilon]

22.11.2006

[URLhttp://sa.iguana2.com/cache/ffb6015f466e0a632b24d4a1e53ed8fb/ASX-XBL-342828.pdf]http://sa.iguana2.com/cache/ffb6015f466e0a632b24d4a1e53ed8fb/ASX-XBL-342828.pdf[/URL]

.

[ixilon]

.
CSIRO assigns additional polymer patent to PolyNovo

29 November, 2006

Xceed Biotechnology Limited (‘Xceed’) is pleased to announce that its 60%
owned subsidiary company, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’) has
today received confirmation of CSIRO's assignment of an additional patent
application to the company. This patent is titled multi-stage curing of
polymers.
The primary difference between this new intellectual property and PolyNovo's
current ‘Cure On Demand’ (COD) technology is that the newly assigned
polymer technology relates to biostable compounds. This significantly
broadens PolyNovo's polymer technology platform.

In commenting on the assignment by CSIRO PolyNovo’s CEO, Dr Ian
Griffiths, said “Having a biostable polymer technology opens up many new
potential applications and adds to PolyNovo future value. Particularly where
the polymers are required to remain safely in patients for the remainder of
their lives. We will be investigating several high potential applications of this
technology over the next few years.”

Further Information:
Dr Ian Griffiths
CEO
PolyNovo Biomaterials Pty Ltd
Mob: [phone]

[ixilon]

29.11.2006

[URLXceed Biotechnology Limited
Annual General Meeting
Presentation
29 November, 2006]http://sa.iguana2.com/cache/14cf31743bae16c847483caf2be41725…[/url]

[ixilon]

30.11.2006

[URLResults of Meeting]http://sa.iguana2.com/cache/0fcb2fc4719b9439f87fb83f2e369a55/ASX-XBL-344014.pdf[/URL]

.

[ixilon]

15.12.2006

[URLNon-Renounceable Issue & Top Up Offer]http://sa.iguana2.com/cache/ed0a8edffad24b3744b8514686bed5e2/ASX-XBL-346124.pdf[/URL]

.

[ixilon]

15.12.2006

[URLDisclosure Document]http://sa.iguana2.com/cache/1a40f1b3244d835f636a37daba7774f9/ASX-XBL-346125.pdf[/URL]

.

[ixilon]

15.12.2006

[URLAppendix 3B]http://sa.iguana2.com/cache/58a1bd6246288915a2830136a1e1b7ef/ASX-XBL-346126.pdf[/URL]

.

[lastsioux]

Hallo ixilon,

hast Du vielleicht mal neue Infos wie es mit der Firma aussieht
hab immer noch Anteile von 2000 finde weder Bilanz noch GUV Zahlen um das Unternehmen bewerten zu können.

Würde mich freuen wenn Du vielleicht etwas Neues hast

Viele Grüße

lastsioux

[Sandel]

Hallo,
ich habe auch noch ein paar von den Dingern und nun ein Bezugsangebot für weitere Aktien bekommen. Weiß jemand näheres dazu?
Gruß,
Sandel

[ixilon]

Hier findet Ihr eigentlich alle Informationen

http://stocknessmonster.com/news-history?S=XBL&E=ASX&Year=20…

[ixilon]

.

Ich wünsche allen ein friedliches und besinnliches Weihnachtsfest.

Liebe Grüße
ixilon

[lastsioux]

Hallo Ixilon,

vielen Dank für die Info.

Wünsch Dir und allen ein frohes und besinnliches Weihnachtsfest mit der Familie und den Freunden.

Viele Grüße
aus Bayern

Lastsioux

[ixilon]

Allen einen guten Rutsch ins neue Jahr, das viel Erfolg vor allem aber Gesundheit bringen soll.

ixilon

[Stammzelle]

Hi ixilon,

bist ja anscheinend der einzige hier, der über diesen Wert einigermaßen gut Bescheid weiß... Du scheinst ja noch etwas von dem Wert zu halten, da du regelmäßig postest.

Habe die "ehemaligen" AMX-Shares auch noch im Depot - ist so eine Art "Mahnmal" und erinnert mich an alte Zeiten, als ich zur Jahrtausendwende alles gekauft habe, was Förtsch empfohlen hat. Hat mich damals ein Paar Zigtausend Euros gekostet - aber naja!!!

Bin auch bezüglich der Kaiptalerhöhung angeschrieben worden und habe nicht vor, dabei mit zu machen.

Würde von dir aber gern Mal eine Einschätzung zu XCEED haben. Ist ja schließlich nicht normal, dass aus einem Unternehmen für Breitbandtechnologie - als solche habe ich die Shares schließlich einmal gekauft - eine Biotechschmiede wird.

In welchem Stadium ist die Angelegenheit mit dem Blinddarm; was machen die noch Mal konkret???

Die Kapitalerhöhung wurde offenbar nicht gut angenommen, weil der Kurs in Australien doch seit Bekanntgabe der Maßnahme merklich zurück gekommen ist.

Schätze Mal, dass die Sache mit dem Blinddarm irgendwann in einer Sackgasse stecken bleibt und es dann ein Ölexplorer wird...



Gruß, Stammzelle.

[bobolo]

Antwort auf Beitrag Nr.: 27.095.439 von Stammzelle am 21.01.07 20:15:56

Hallo Stammzelle,

ich bin auch noch investiert und werde die Erhöhung mitmachen. Es heisst zwar immer, daß man gutes Geld nicht schlechtem Geld nachwerfen soll - aber die paar Hunderter investier ich auch noch.
Was mich wundert ist die Tatsache, daß die offizielle Information nur von einem Bezugsrecht für in Australien mit Wohnsitz gemeldeten Aktionären spricht und trotzdem hat meine Bank mich angeschrieben. Entweder ich hab eine Informationlücke oder warum geht das. Kann mich jemand schlaumachen.
Ansonsten hätte ich auch gern mehr Information falls jemand was an der Hand hat.

bobolo

[Stammzelle]

Hi,

wer kann denn etwas zu den Aussichten von XCEED sagen. Für welche Projekte wird das Geld benötigt?

Macht noch jemand außer bobolo bei der Kapitalmaßnahme mit?


Gruß, Stammzelle.

[Stammzelle]

Antwort auf Beitrag Nr.: 27.143.326 von bobolo am 24.01.07 09:40:40

Hi bobolo,

meine Bank hat zu dem "Wohnsitzproblem" folgenden Hinweis gegeben:

"Aktionäre mit Wohnsitz außerhalb von Australien müssen sicherstellen, dass die Annahme nicht gegen gültiges Recht des jeweiligen Landes verstößt. Dieses Schreiben dient lediglich Ihrer Information und bedeutet nicht, dass Sie berechtigt sind, an der Maßnahme teilzunehmen. Wir empfehlen Ihnen, dies zu prüfen und gegebenenfalls mit einem Rechtsberater zu besprechen."

Bei einem Bekannten hat die Depot führende Bank dieses Problem (die Belehrung) überhaupt nicht erwähnt.

Weiß jemand mehr über die Rechtslage?


Gruß, Stammzelle.

[bobolo]

Antwort auf Beitrag Nr.: 27.262.808 von Stammzelle am 28.01.07 22:22:36

Hi Stammzelle,
danke für Deine Antwort und den Hinweis. Da meine Bank hier keine Information in diese Richtung gegeben hat, gehe ich davon aus, daß sie geprüft hat, inwieweit das Bezugsrecht auch von deutschen Inländern ausgeübt werden kann. Ich sehe der Sache relativ gelassen entgegen. Spätestens bei der Zuteilung müsste hier schon seitens der Firma ein Veto kommen.
Abwarten und Tee trinken

bobolo

[Stammzelle]

Hi,

klappt wohl nicht so recht mit der Kapitalerhöhung. Haben die Frist jetzt noch Mal verlängert. Kommt wohl bei den Aktionären wirklich nicht gut an...

Wer hat von euch denn jetzt mitgemacht?

Nenne mir Mal jemand einen handfesten Grund, warum man Aktien dieser Firma besitzen MUSS!
Offenbar kennt sich aber wohl niemand hier im Board damit aus, was die tatsächlich machen...




Gruß, Stammzelle.

[Stammzelle]

Hi,

weiß jemand, warum der Kurs seit einigen Tagen nach oben dreht? Hängt es mit dieser Veröffentlichung zusammen?

http://www.xceedbiotech.com/files/TDNBEUNCHA/Supplementary%2…

Oder wird der Kurs jetzt nur durch gezielte Käufe für die Kapitalmaßnahme etwas "attraktiver" gemacht?

Oder gibt es einen ganz anderen Grund? Am Freitag war das Handelsvolumen in Australien war mit 3,5 Mill. gehandelten Shares schon okay!



Gruß, Stammzelle.

[gerdass]

Antwort auf Beitrag Nr.: 12.901.602 von ixilon am 28.04.04 11:27:10

[ixilon]

[ixilon]

6 Monatschart

[Stammzelle]

Hi,

hat jemand eine Erklärung für den Kursanstieg?


Gruß, Stammzelle.

[ixilon]

NovoSkin commences pre-clinical trial with its
Biodegradable Temporising Matrix

7 May, 2007

Xceed Biotechnology Limited (ASX:XBL) (‘Xceed’) is pleased to advise that its subsidiary company, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’) has commenced a pre-clinical trial utilising its dermal scaffold product made from NovoSorb™.
This study is being conducted by NovoSkin, PolyNovo’s joint venture with eminent Adelaide burns surgeon, Dr John Greenwood AM. The study will determine the efficacy of PolyNovo’s Biodegradable Temporising Matrix (BTM) in a wound model. This trial builds on the earlier successful work NovoSkin has conducted into the safety of NovoSorb and the advantages of the BTM.
The trial is designed to assess the healing response, scar size and resistance to contraction wound in a wound healing environment. This trial is due to be completed by the end of July 2007. The data will undergo detailed analysis and we expect to make an announcement of the results by the end of October.
NovoSkin’s Clinical Director, Dr John Greenwood said “When the size of a burn injury exceeds the available area for harvesting skin grafts, there is a significant risk of patient morbidity. Our aim is to produce a cheap, any size, easy to store and use dermal scaffold that will have enormous utility in the treatment of severe burns and may also save patient’s lives. NovoSkin’s clinical studies will provide key data for the development of NovoSkin’s BTM product and the expected positive outcomes could lead to a breakthrough in burns treatment and a major change in clinical practice.”
PolyNovo’s CEO, Dr Ian Griffiths, commented further “The successful development of BTM will not only provide enormous utility for burns surgeons but may also allow far wider application of the product in the treatment of trauma and the large market area of cosmetic surgery.”
...

Quelle : http://sa.iguana2.com/cache/343aef50643ef79c3ad707d98569b33d…

[ixilon]

Frohe Pfingsten

ixilon

[ixilon]

[Stammzelle]

Hi,

hat jemand eine Ahnung, was los ist? +37% unter nicht allzu hohem Volumen in Australien?


Gruß, Stammzelle.

[ixilon]

Xceed to Demerge PolyNovo in conjunction with an IPO

19 July, 2007

Xceed Biotechnology Limited (‘Xceed’) is pleased to advise that it will seek shareholder approval for the demerger of its 64% owned subsidiary company, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’). This is planned to occur in conjunction with an IPO of PolyNovo on ASX.

The demerger would be achieved by Xceed distributing in-specie all of the shares it holds in PolyNovo to Xceed’s shareholders. This will be subject to shareholder approval of resolutions to be put to a general meeting of Xceed shareholders, likely to be held in late August or early September 2007.

PolyNovo has commenced preparation of a Prospectus for the issue of fully paid ordinary shares to allow it to carry out the IPO. Details of the capital to be raised under the Prospectus and pricing of the issue will be released as soon as they have been confirmed by PolyNovo. Should PolyNovo shares be offered generally as part of this process, anyone wishing to acquire PolyNovo shares in the IPO will need to complete the application form in the Prospectus, which is expected to be available in early September, 2007.

Subject to (i) approval of the demerger by shareholders at the forthcoming general meeting and (ii) the PolyNovo IPO proceeding, Xceed shareholders at the record date (to be notified in the Notice of Meeting documentation) will receive a free equitable distribution of PolyNovo shares in accordance with their shareholding in Xceed.

The demerger and IPO plan is intended to optimize the value of PolyNovo in the context of the recent significant growth in PolyNovo’s future business prospects and facilitate the provision of capital to fund that growth. In addition to the collaborations with its existing licensing partners, Medtronic, Inc. and Biomet, Inc., and those under the NovoSkin joint venture, PolyNovo has numerous other highly prospective options for the commercialization of NovoSorbTM. In order to maximize this potential, the Xceed Board believes that PolyNovo should have direct access to the Australian capital markets.

Xceed will keep shareholders informed of the demerger process with a further release of information likely to be in the next two to three weeks when it is planned to distribute the Notice of Meeting for the abovementioned shareholder meeting.

Further Information:
Mr David Kenley
Chief Executive Officer
Xceed Biotechnology Ltd
Ph: [phone]
Mob: [phone]

Mr David Williamson
Company Secretary
Xceed Biotechnology Ltd
Ph: [phone]
Mob: [phone]

PolyNovo Biomaterials Pty Ltd

PolyNovo’s technology is titled NovoSorbTM and is based on novel composition of matter and process patents developed within CSIRO’s Division of Molecular and Health Technologies.
PolyNovo is focused on commercialising NovoSorbTM to produce a range of medical products that can be safely broken down and excreted (biodegradable) and utilised (bioresorbable) by the human body. NovoSorbTM offers flexibility which allows it to be formulated either as an injectable gel that can be cured in-situ or on demand or as a solid form product with the compressive strength similar to bone. Degradation time can be pre-set according to use and can range from as little as a few days to multiple years.
NovoSorbTM can be tailored to large world markets with potential applications in the areas as diverse as orthopaedics, orthodontics, drug delivery, wound care, tissue engineering, nerve regeneration and cartilage repair. For more information, please visit the company’s website at www.polynovo.com

Xceed Biotechnology Ltd

Xceed Biotechnology Limited is a biotechnology company based in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: XBL). Historically, Xceed has worked closely with CSIRO to successfully spin-off two companies. These companies, Boron Molecular Pty Ltd (100% owned) and PolyNovo Biomaterials Pty Ltd (owned 64% by Xceed with the remaining 36% interest owned by CSIRO) both commenced with exclusively licensed or assigned core technologies developed by CSIRO. Xceed’s primary focus is to provide PolyNovo and Boron with the resources necessary to ensure their technologies are successfully commercialised.
For more information, please visit the company’s website at www.xceedbiotech.com

[ixilon]

4 Jahreschart

[ixilon]

Xceed Biotechnology soars on plans to split off PolyNovo

19/07/2007 By: Andrew Nelson

Shares in Xceed Biotechnology Limited (XBL) rallied more than 40% after it announced it would look to demerge its 64% owned subsidiary, PolyNovo Biomaterials. The company said it would distribute all of the shares it holds in PolyNovo to its shareholders, which would occur in conjunction with an IPO of PolyNovo on ASX.

In a statement to the market, the company said that the demerger and IPO plan is intended to both optimise the value of PolyNovo after recent significant growth in PolyNovo’s future business prospects and to facilitate the provision of capital to fund that growth.

In addition to the collaborations with its existing licensing partners, Medtronic and Biomet, and those under the NovoSkin joint venture, PolyNovo has numerous other highly prospective options for the commercialization of NovoSorbTM, the company explained.

PolyNovo said it has commenced preparation of a prospectus for the issue of fully paid ordinary shares to allow it to carry out the IPO.

In order to maximize this potential, the Xceed Board believes that PolyNovo should have direct access to the Australian capital markets.

The biotech investment company said that the demerger is still subject to shareholder approval and that a general meeting would likely be held in late August or early September 2007.

In the meantime, Xceed said it would keep shareholders informed with a further release of information likely to be in the next two to three weeks.

At 1124 AEST, shares in Xceed Biotechnology had rocketed 6.5c, or 37% to 24c .

Quelle : http://www.egoli.com.au/egoli/egoliStoryPage.asp?PageID=%7B7…

[ixilon]

Xceed share price up 37% following PolyNovo demerger talk

19-July-07 by Edited announcement

The announcement of Applecross-listed and Victoria-based Xceed Biotechnology Ltd's plan to demerge subsidiary PolyNovo Biomaterials Pty Ltd through an initial public offer sent the company's stock up 37 per cent, closing at 24 cents today.

Xceed plans to distribute its PolyNovo shares in-specie to its shareholders, telling the market today the demerger would optimise the subsidiary's value in light of the recent growth of its business prospects.

PolyNovo, which specialises in the manufacture of biodegradeable polymers, is part-owned by the CSIRO.
...

Quelle : http://www.wabusinessnews.com.au/en-story/1/55067/Xceed-shar…

[ixilon]

26.07.2007

[URLPolyNovo - Exclusive Negotiation with Large Device Company]http://sa.iguana2.com/cache/064dcdb7d7f313a6cf258ab01b62a8a0/ASX-XBL-370284.pdf[/URL]

[ixilon]

.

XCEED BIOTECHNOLOGY LTD [URLNEWSÜBERSICHT]http://stocknessmonster.com/news-history?S=XBL&E=ASX&Year=2007[/URL]

.

[ixilon]

Update on Demerger and IPO of PolyNovo

31 August, 2007

On 19 July 2007, Xceed Biotechnology Limited (‘Xceed’) announced that it would seek shareholder approval for the demerger of its 64% owned subsidiary company, PolyNovo Biomaterials Pty Ltd (‘PolyNovo’) and that this was planned to occur in conjunction with an IPO of PolyNovo on ASX. Xceed also advised that this would be subject to shareholder approval of resolutions to be put to a general meeting of Xceed shareholders, likely to be held in late August or early September 2007.
Significant preparatory work for both the Xceed Notice of Meeting and PolyNovo Prospectus has already been completed and this work remains ongoing. However, an IPO will not be completed within the timeframe announced in July 2007 due to the stock market volatility experienced over recent weeks. PolyNovo is currently actively exploring several means by which an IPO can be completed within an appropriate timeframe.
A further update will be provided to the market as soon as the company is in a position to do so.
...

Quelle : http://sa.iguana2.com/cache/2082b4bdc3e759912cc7d029cde9cd6d…

[ixilon]

Ich wünsche allen frohe Weihnachten

ixilon